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PREFACE 
The chief problem at present with artificial heart valves is their 
thrombogenicity, which requires the recipients to undergo 
dangerous anticoagulant therapy, which is not always successful. 
The present accepted method of testing valve thrombogenicity is 
implantation in experimental animals. This technique is unsatisfactory 
because of its high cost, the lack of control, the length of the 
experiments and because differences between the blood of various 
species render the results of dubious value. A more fundamental 
approach to the problem based on fluid mechanics'fails because 
of the complexity of the situation and because of the opposed effects 
of a given fluid mechanical phenomenon. The in vitro use of blood 
is not possible due to the need for a single pass system to avoid 
recirculating clots, necessitating some thirty gallons of blood for 
a run of only one hour. 
An analogue method using a fluid which does not have the 
disadvantages of the alternatives described above, therefore, seems 
worth exploring. Rennetized milk is a possible fluid for such a 
purpose and experiments were performed to ascertain whether it 
behaves in a manner analogous to blood in respect of its essential 
clotting properties. The first indications from the Lee-White 
inverted test tube test were very promising with milk behaving in a 
manner apparently identical to blood. Further experiments using the 
Stagnation Point Flow Chamber showed that there was a striking 
similarity in the microscopic appearance of the deposits forming at 
and around the stagnation point when a jet of milk/blood impinges 
normally onto a glass slide. A subsequent experiment, in which the 
fluids are pumped through a mesh, revealed that the sequence of clot 
growth as measured by the pressure variation upstream of the mesh is 
the same for both fluids. Finally, full scale tests of the clotting 
propensity of various heart valves were performed using an artificial 
heart system, which showed that the location and appearance of the 
clots forming on the valves with rennetized milk were similar to 
those found in humans and that the results were reproducible. It 
is, therefore, apparent that rennetized milk shows great potential 
as an analogue for the flow related clotting of blood and can be used 
for testing artificial heart valves provided care is taken in the 




With the dramatic increase in the number and variety of 
artificial devices implanted over the past twenty years, 
it has become increasingly important to find a method for 
predicting the thrombogenicity, not only of' the materials 
used, but of' the whole device. 
1.1 Animal Implantation 
At present the accepted method of estimating the probable 
clotting effects in human patients is to implant the device 
in animals of various species; if the results are satisfactory, 
clinical trials are supposed to be justified. However, the 
differences in the blood characteristics of these species 
are very great, and the usefulness of animals as models for 
the clotting response of the human ., ystem 
is questionable. 
This uncertainty is highlighted by Grabowski et al, who 
studied platelet adhesion to foreign surfaces, under controlled 
conditions of whole blood flow, using an in vitro system in 

















Fig 1. Flow chamber used by Grabowski et al. 
Human, rabbit, dog, calf, sheep, pig, macaque and 
baboon blood were used and they reached the following 
conclusions: 
1) At a shear rate characteristic of those found in 
mammalian arteries, human platelet adhesion ( and 
that of calf, baboon, macaque, hog or sheep) is 
negligible in comparison to dog or rabbit platelet 
adhesion after 10 minutes of blood flow through their 
chamber. 
2) The species differences are biomaterial dependent; 
the human-dog difference being present with Cuprophan 
or Avcothane, but absent with compressed Coretex or 
fluorinated ethyl-cellulose. 
PLATELETS/mm2 
(Mean i SE, N)* After 10 mans of Blood Flow at a Surface Shear Rate of 986 sec') 





Human < 100 (4) < 100 5,600 t 1,500(4) 5,600 t 5,000(4) 
Dog 27,400 t 4,600(5) 19,400 t 9,300(4) 3,600 t 1.600(4) 5,500 3 3,500(4) 
Rabbit 78,400 t 6,400(4) - - - 
Calf < 100 (4)\ - 13,500 t 9,800(5) - 
Baboon, 
Macaque, 
< 100 (4)+ - - - Hog, or 
Sheep 
*N is the number of different subjects or animals. 
+N -4 for each of the 4 species listed. 
Fig. 2 Table showing numbers of platelets adhering to 
chamber surface found by Grabowski et al. 
Their final conclusion is that, since platelet adhesion 
plays a fundamental. role in thrombus formation, tests 
for thromboresistance of candidate biomaterials and for 
platelet adhesion, even under controlled flow conditions, 
must take into account differences between human blood 
and that of other species. 
a 
3 
A further implication is that the ranking order of such 
materials may vary with the animal species used in 
the experiments. Mills (2), using a turbidimetric 
technique to measure the degree of platelet aggregation 
by ADP on blood derived from animals of difference 
species, also found marked differences between the 
species. He concluded that investigations of the 
participation of platelets in thrombosis, in experimental 
models, could lead to some very misleading results, if 
species differences were not somehow taken into account. 
There are other disadvantages in relying on animal 
trials as the primary means of testing thrombogenicity: 
1) As well as the differences in the blood characteristics 
of the various species, there are other marked 
physiological differences, which may affect the results. 
For instance, the pulse rate of the dog is very much 
faster than that of man; and the calf, much used 
in definitive tests of artificial hearts and heart 
valves, is an infant which will grow throughout an 
experiment and it is not clear how that fact will 
affect its blood clotting. An example of animal 
5 
trials yielding misleading results if)given by 
Starr (3), who found excessive tissue growth on his 
ball valve, when it was tested in dogs, which was not 
found in clinical trials. To overcome this he 
designed a silicone shield for the valves when they 
were being tested in dogs. 
2) The cost of the experiments is high, as a full 
surgical team is required, operating under sterile 
conditions, and the animal must be maintained and 
housed throughout the trial. The high cost means 
that in many cases it is only possible to test a 
"finished" device and it is not possible to test the 
thrombogenicity of alternative versions or modifications 
throughout the development period. 
L. 4- 
3) Animal tests are very lengthy. 
4) There is a lack of control of the experiments by the 
designer of the device as he is dependent on the 
skill of the surgical team, the suppliers of the 
animals producing healthy specimens, the animal 
keeper maintaining the animals properly, and the vet 
or surgeon performing the removal of the device 
without disturbing any formed clot. 
5) Ethically, if there is a possible substitute for 
animal experimentation, it should be developed and 
used (4). 
1.2 The Hydrodynamic Correlates of Thrombosis 
The crudely empirical method of using animal trials 
for testing the complete device having proved 
unsatisfactory, it is natural to enquire whether a 
more fundamental or mechanistic approach to blood 
clotting effects might not prove more advantageous. 
Virchow in 1856 (5) announced that a triad of factors 
was important in coagulation: (i) surface chemistry, 
(ii) hydrodynamics, (iii) blood chemistry. 
Accordingly, a plausible technique for evaluating 
thrombogenicity, associated with the physical design 
of a prosthesis, depends on the assumption that one 
can identify the hydrodynamic factors predominant in 
causing clotting. By measuring the extent to which a 
prothesis is associated with these factors, it should 
in principle be possible to infer its likely propensity 
to cause clotting. 
Much work has been done on the hydrodynamic aspects of 
clotting and among the phenomena which have been 
considered to be important are: 
(1) Shear Stress, 
(2) Stagnation, 
(3) Mass Transfer. 
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These will now be considered in turn. 
1.2.1 Shear Stress 
The effect of shear on thrombogenesis is confused; 
by damaging the cellular components of blood, shear 
stress can cause the release of chemicals, such as 
A. D. P. and A. T. P., into the plasma, which enhance 
coagulation and platelet aggregation. On the other 
hand shear can also damage the species involved in the 
clotting mechanism, such as the platelets, factor X 
and prothombin, and hence, inhibit coagulation. 
Shear can also prevent adhesion to the surface on 
which it acts and affect the structure of any clot 
forming on the surface. It may also cause damage to 
to the lining of blood vessels, which can in turn 
lead to thrombus formation. 
ADP and ATP Effects 
The red blood cells or erythrocytes contain A. D. P., 
which i3 a powerful platelet aggregating agent, and a 
clot promoting factor known as erythrocytin. If the 
cell is damaged or ruptured, (haemolysed) these 
substances are released into the blood plasma (6,7, ), 
which may lead to a hypercoagulable state (8,9) and 
platelet aggregation-adhesion resulting in thrombus 
formation (10 - 17). Thus all haemolytic agencies 
are potentially thrombogenic and since thrombosis leads 
to further haemolysis of the cells involved in the 
thrombus the effects are cumulative. 
Tillmann et al (18,19) suggest that a local platelet 
activation seems possible during diastolic regurgitation 
by the NTP released from sublethally damaged 
erythrocytes. During the following ejection phase, 
platelet aggregation can take place in the next deadwater 
region, which is located downstream of the small orifice 
area at the disc of the Bjork-Shiley heart valve, or the 
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Lillehei-Kaster valve and it is here that thrombus 
formation is often observed in clinical practice 
(20 - 23). 
Shear stress appears, in some circumstances, to enhance 
and in others to reduce, deposition and aggregation 
effects. It is not clear how these opposite effects are 
related to different shear situations. 
Anderson et al (24), using a rotational viscometer to 
study the effects of shear stress on human platelets in 
platelet rich plasma, found that the platelet count in the 
shear field was reduced by aggregation, from an initial 
count of 300,000, to as low as 60,000, for a shear stress 
of 200 - 400 dynes / cm2 applied for 30 seconds. They 
found no measurable lysis under these conditions, but, 
the function of the remaining unaggregated platelets was 
impaired, as indicated by the reduced aggregation by ADP. 
This result is supported by work by Dewitz et al (17), 
from the same laboratory, using whole blood instead of 
platelet rich plasma, and by Hung et al (25). 
Inhibition by Damage to Clot Promoters 
As well as its ability to inhibit the ADP aggregation of 
platelets, shear stress has been shown to decrease the 
activation rate of factor X in the intrinsic pathway (26), 
and Spaeth et al (27), using a laminar flow tubular reactor 
to generate a well defined shear stress environment, have 
shown a dramatic reducing effect of fluid shear on the 
conversion of prothombin to thrombin. Furthermore, 
Charm and Wong (28,29) have shown that some enzymes, 
when subjected to shear, lose activity as a function of time 
and shear rate and that plasma fibrinogen, in vitro, 
suffers a loss of clottability due to shearing. 
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Effect of Shear on Adhesion and Clot Structure 
Glover et al, (30,31) and Roberts et al (32) have shown 
that graded shear stress can have marked effects on clot 
structure formation. Under shear the mechanical strength 
of the clot formed can be a factor of five weaker, the 
initiation time shortened and the initial polymerization 
rate doubled. They also found that shear stress can cause 
the formation of platelet aggregates, which may be 
important in the thromboembolic phenomena or thrombosis 
associated with the extended use of blood contacting 
devices. 
Petschek et Al (11,12,33, ) using the stagnation point 
flow chamber described later, found that increasing the 
shear stress decreased the amount of material deposited 
onto a surface, leading to discrete white cell circles of 
radius limited by the applied shear stress. 
Grabowski et al (15,16) found that platelet aggregate 
growth rates appear to be limited at low shear rates by 
platelet convection, but at higher shear rates by dilution 
of A. D. P., finite platelet - A. D. P. reaction times and surface 
shear stress. This may resolve the foregoing conflicts. 
Another means by which shear can lead to thrombosis is 
described by Yoganathan et al (34,35) who found that at 
a downstream distance of about 12 cm from a prosthetic heart 
valve, the wall shear stresses were of a magnitude that 
could damage the endothelial lining of the ascending aorta 
and the coronary arteries, and lead to thrombus formation. 
Physical Aggregation 
The basic theory of the purely physical aggregation of 
particles by simple contact in a colloidal suspension 
was worked out by Smoluchowski (36). When coagulation is 
controlled by Brownian diffusion, the kinetics of the decay 
of the total particle concentration, N*, is 
approximately 2nd order, i. e. 
dN* =- 4aGb N*, where a is the collision 
dt -r 
frequency in shear flow, G is the shear rate and b is the 
volume fraction of suspended particles. 
This supports the theory that by increasing the shear 
rate, the rate of aggregation is increased. 
Conclusion 
In conclusion, shear will not normally cause clotting 
to occur in situ and the presence of a high level of 
shear on a surface will tend to prevent the build up 
of any thrombus. However, by causing aggregating agents 
to be released into the plasma, it may well promote 
thrombosis elsewhere by causing the blood to become 
hypercoagulable. 
1.2.2 Stagnation 
Stagnation is considered by many authors to be one of 
the prime causes of thrombosis (11,12,20,33,37 - 42). 
There are two distinct types of stagnation which are 
considered important, the first of which is caused by 
flow impinging at right angles to a surface (stagnation 
in the strict fluid dynamicist's sense), while the second, 
more accurately termed stasis, is associated with flow 
regions in which the residence time is greater than 
local volume ). These are sometimes, quiet"- 
mean fluid velocity 
pockets of fluid and sometimes regions of recirculating 
flow. Petschek's group (11,12,33) have looked at the 
first of these two types of stagnätion and its effect on 
blood deposition, using their stagnation point flow chamber 
in which blood from the carotid artery of an anaesthetized 
dog impinges perpendicularly onto a slide on which the 
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thrombus forms. This work is described later. Most other 
investigations have been concerned with stasis. 
Leonard (42) and Morton (43) have shown that the presence 
of a captured vortex greatly enhances platelet deposition, 
and Yoganathan (20) has shown a direct correlation between 
the areas of stasis on the Bjork-Shiley heart valve and the 
areas of thrombus formation and apparent tissue overgrowth. 
As the presence of a foreign surface is known to promote 
thrombus formation (10,12,41,44-50) it is not suprising 
that increased blood residence time in the vicinity of the 
surface should lead to enhanced thrombus deposition. 
1.2.3 Mass Transfer 
The rate of deposition of blood particles onto a surface will 
be affected by the rate at which those particles are brought 
to the surface. Hence, it is reasonable to suppose that the 
mass transfer coefficient, which is a measure of this 
transport phenomenon, might be related to the blood clotting 
propensity of a given flow environment. The mass transfer 
coefficient at a point on a surface is generally closely related 
to the shear stress at that point and this is certainly true 
of flow parallel to a surface. However, if one considers the 
case of a jet of fluid impinging perpendicularly onto a 
surface, at the central stagnation point the shear stress is 
zero and rises radially outwards within the impingement zone, 
while the mass transfer coefficient remains constant throughout 
the same region. 
Since impingement is one of the causes of deposition of blood 
onto surfaces (11,12,33,41) and the relationship between 
mass transfer and shear stress clearly breaks down under 
that circumstance, it is worthwhile to check whether the 
mass transfer coefficient is more closely related to blood 
clotting propensity than is the shear stress. 
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There is considerable evidence to support a correlation 
between blood clotting and mass transfer rates, Knight et 
al (51) found clot on the unfaired edge of the ring and on 
the upstream side of the disc at the location of which the 
blood leaving the sharp edged orifice would impinge. The 
mass transfer rates are very high at these points and when 
a faired ring was substituted, these patterns of deposition 
disappeared (52). Gott (53) found that when short segments 
of rigid tube were implanted in dogs, those with bluff or 
abrupt end faces or edges were much worse than those tubes 
with streamlined trailing and leading edges, at causing 
thrombus deposition. This one would expect from the mass 
transfer characteristics of these flow situations. 
Several other authors (12,13,40,54) have done work which 
supports the assertion that mass transfer and blood clotting 
propensity are related, but Taylor (55,56) and Vorhauer (57) 
have shown that there are exceptions to the correlation. 
Vorhauer implanted a variety of bodies into the canine aorta 
and weighed any shed thrombus downstream. The order of ' 
thrombogenicity was found to be: disc, ball, upstream apex- 
cone, tear-drop. However, in terms of mass transfer 
characteristics the order would be: cone, disc, ball, tear- 
drop, so there are limits to the relationship. Furthermore, 
Taylor found that, when investigating the deposition phenomena 
found in Petschek's stagnation point flow chambers, there 
was no correlation between the mass transfer coefficients 
and the radius of the white cell circles formed. 
Although there is clearly likely to be a relationship between 
mass transfer and blood deposition, it evidently does not 
hold universally in the expected form. 
1.2.4 Other Fluid Mechanical Phenomena 
There are other fluid mechanical pehnomena, which may be 
important in coagulation. Heller (58, " 59) has shown that 
colloidal coagulation in a`turbulent regime is greatly 
enhanced by the presence of a single bubble. 
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Ward (60) and Balderman (61) have shown that the removal 
of gases from blood decreases its propensity to form 
clots, both in vitro and during cardiac surgery, if a 
single bubble were introduced into, or generated by 
cavitation in, the fluid in the region of a heart valve, 
for instance, platelet aggregation might well be greatly 
enhanced. This is borne out by observations of deep sea 
divers during decompression (101-103), where microbubbles 
are released into the blood stream and enhanced platelet 
aggregation occurs. On the Bjork-Shiley valve, one of the 
heart valves associated with thrombosis problems (21,23, 
62-64), the presence of an obstruction to the flow - in 
this case a disc not opening fully - can create vortices 
in the valve field. If a series of small bubbles were 
introduced into these vortices, greatly enhanced coagulation 
and deposition onto the valves might be expected. Since 
blood contains large volumes of dissolved gases, a small 
negative pressure, which has been shown'to exist in the 
region of the valve (65), may be sufficient to dissociate 
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bubbles, and hence cause clotting and aggregation. However, 
Bernstein et al (66) found that, using a jet stream injection 
device designed by Forstrom (67) to provide controlled shear 
stress fields, no significant changes in the oxy-haemoglobin 
dissocation curve were observed. 
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Thus the incidence of clotting on, for instance, the Bjork- 
Shiley valve might be due to any or all of the following 
fluid mechanical factors: - negative pressure (causing 
cavitation), high shear stress during the opening and 
closing cycles, trapped turbulent vortices and stagnation 
over a large area. There is, at present, no obvious way of 
isolating these possible causes, or assessing the effect of 
design changes on individual factors for the Ejork-Shiley valve. 
Thy hydrodynamic correlates of clotting phenomena are therefore 
extremely complex, and it is accordingly unlikely that a 
hydrodynamic study by itself using continuum fluid mechanics 
could ever satisfactorily be used to predict the propensity 
of a device to clot. Effler (68) goes so far as to suggest 
that the deposits found on heart valves are not clots in 
the accepted sense of the word, but, a rejection mechanism 
due to the treatment of the sewing rings in the bleaching 
process. 
An explanation for some of the confusion as to the cause of 
clots by different authors may be as follows. Itzseems 
probable that there are two distinct types of deposition 
which may occur. One is caused by the presence of a site, 
which due to some local fluid mechanical, or surface effect, 
acts as an inception point from which a thrombus may grow. 
A clot caused by this will be of a discrete nature. The 
other type of deposition is caused by a change in the blood 
chemistry, possibly due to haemolysis, which creates a state of 
hypercoagulability. The deposit found then will be very much 
more general in nature, much as described by Effler, which seems 
much more plausible than a rejection mechanizm. 
1.3 The Use of Blood In Vitro 
In view of these difficulties, in the way of a more 
fundamental approach to the prediction of thrombogenicity, 
one is forced to consider more directly empirical methods. 
One such technique, alternative to the use of in vivo 
methods of assessing thrombogenicity, is the use of blood 
in an in vitro system. Working in vitro removes the problem 
of lack of control over the experiment, but, due to the 
differences between human and animal blood, the use of 
human blood would be desirable in such experiments. 
A sing'_e pass system is vital to avoid recirculating clots, 
and the flow rates and conditions must approximate to those 
foýind in vivo. For this reason, an apparatus such as that 
used by Wright (69) for testing the haemolysis caused by 
prosthetic heart valves could not be used to give 
realistic indications as to the likely propensity of valves 
to cause clots. It is also very difficult to use blood 
in vitro without treating it with anti-coagulants at some 
stage, and, although the anti-coagulant properties can be 
reversed, one cannot know exactly how this will affect the 
coagulative properties of the blood. The risk of infection 
to the experimenters, many of whom may be engineers, unused 
to working with blood, cannot be overlooked, and it is difficult 
to obtain sufficient blood, even animal, for experiments on 
the most moderate scale. 
1.4 Blood Analogue 
A possible solution to these difficulties would be to use a 
blood analogue, that is to say, a fluid whose behaviour in the 
relevant circumstances has been shown to be similar to the 
behaviour of blood. This fluid must be: - readily available, 
of reproducible properties and composition, cheap, safe to 
use, and as similar as possible to blood in respect of its 
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essential clotting properties and in the adhesiveness and 
rheology of the formed clot. The last of these is important, 
since thrombus formation is a cumulative process and once 
a deposit has begun to form it is important to be able to 
observe its development. 
Several fluids have been used for coagulation studies, FeOOH 
sol by Heller (58), FeOOH and CuO sols by Freundlich (70,71) 
Dow polychlorostyrene latex by Heller and Delauder (72), and 
magnetite or Fe304 was used by Newson (73). 
If one is to mimic the coagulation and deposition of blood 
which is a biological fluid, and whose clotting is due to the 
action of a specific enzyme, thrombin, it would be appropriate 
for the analogue to have similar characteristics. None of the 
fluids listed above has these properties, whereas rennetized 
milk does. Other less well known and more obscure enzymatic 
clotting processes are; - the conversion of ovalbumin into 
plakalbumiri by subtilisin (74), and the formation of collagen 
fibres from procollagen by procollagen peptides (75). 
Since it is not proposed that the analogue shbuld be able to 
mimic those effects which are attributable to blood chemistry 
or surface effects, but merely those relating to hydrodynamic 
effects, it is not essential that there should be any more 
than a gross overall similarity between the fluid used and 
blood itself. However, it is worthwhile to consider milk, 
blood and their coagulation reactions to see if there is any 
great similarity between them, as several authors have remarked 
upon this. 
The idea that milk should behave analogously to blood is not 
new, for as Thomas Coghan said in 1584 (76), "Milke is made 
of bloude twice concocted ....... for until 
it comes to the 
paps it is plain bloude, but afterwards by the proper nature 
of the paps it is turned into milke, " and in the 9th century 
Isaac Israeli said, "Lac non est aliud nisi sanguis 
coctis in uberibus" (77). 
Many people have noted the similarity between the 
coagulation of blood and milk, notably, Berridge 
(78,79), in whose work on the adhesion of coagulating 
casein to various surfaces, a curious phenomenon was 
observed: when a section of beef aorta had coagulating 
casein passed over it, no deposition was found on the 
surface which would normally be in contact with the 
blood, but a large quantity of deposit was observed on 
the cut ends. Scott-Blair (80,81,82) has done a great 
deal of work on the coagulation of both milk and blood, 
ani has noted the similarities between the two. Jolles 
(83,84) compared the structural aspects of the clotting 
of milk and blood, and showed that, although there are 
obvious differences between the two, there is an overall 
similarity. He concludes as follows: - "That the enzymatic 
cleavage of both fibrinogen and k-casein may proceed via 
similar mechanisms is suggested from the evidence that 
(a) a certain degree of homology exists between the 
primary structures of cow k-casein and the Bb and 
chains of human fibrinogen and (b) the sequences 
surrounding the thrombin/chymosin-sensitive linkages of 
these two proteins determine in their part their 
susceptibility to thrombin/chymosin hydrolysis. The 
chemical modification studies on fibrinogen together with 
the recent work carried out on k-casein, support this 
hypothesis and indicate that the histidine residues of 
both k-casein and fibrinogen, especially those of the 
Bb chain, play an important part in the interactions 
between these two proteins and their respective 
pro teases". 
1.5 The Milk Clotting Process 
The clotting of milk by chymosin, the predominant 
protease in the fourth stomach of the young calf, 
includes three main phases. The first of the phases 
is the action of the chymosin on k-casein, the protein 
in milk involved in the clotting process, and involves 
the release of caseino(glyco)peptide (85). The second 
is the formation of the coagulum, which is caused by the 
casein micelles aggregating in the presence of calcium 
ions, and in the third phase (86) the casein components 
are slowly hydrolized. 
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Approximately 80% of the protein in milk is present as a 
stable suspension of relatively large spherical calcium 
proteinate-phosphate particles, called micelles, which 
vary in diameter between 40 and 300 nm. (90). The 
micellar protein, or casein, consists of two groups of 
components, one soluble and the other insoluble in the 
presence of Cat+; the insoluble components are as-casein 
and b-casein, whereas k-casein is soluble. The k-casein 
stabilizes colloidal dispersions of calcium caseinate and 
is identified by Waugh and von Hippel (91) as the 
protective colloid. A number of different models have 
been proposed to describe the structure of the casein 
micelle. There are two distinct fields-of thought: on 
the one hand that all the k-casein is located on the 
coat (92); alternatively, that it is distributed 
throughout the micelle (93). However, recent evidence 
suggests that both are true and k-casein is located 
within the micelle as well as on the surface (94). 
The micelle-stabilizing properties of the k-casein are 
destroyed by the action of the chymosin; a phenylalanyl- 
methionine linkage is split (95), yielding a soluble 
fraction containing the caseinoglyco-peptide and an 
insoluble para-k-casein, which complexes with as-casein 
and forms the strands of the clot (96). This can be 
summarized as follows: 
mosi k-casein chyph 6ý para-k-casein + caseinoglyco-peptide 
(insoluble) (soluble) 
Green (97) and Doolittle (98) have shown the importance 
of Ca2+ concentration on the rate of aggregation in the 
secondary phase of the milk clotting process. The 
secondary phase is not yet fully understood, but it does 
not appear to happen until the substate has been completely 
modified {99), although there is some doubt about this 
(100). 
The clotting time, being the time till completion of 
the secondary stage, is usually inversely proportional 
to the concentration of chymosin. Temperature is very 
important; increasing temperature decreases the clotting 
time, although temperatures above 430 c will render the 
enzyme less active. Ph is also important; the clotting 
time falling with falling Ph (104). 
There are other mechanisms by which milk can be coagulated 
namely; heat coagulation (105,106) and through souring, 
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where development of lactic acid hastens coagulation 
(104). 
The process of milk coagulation is not yet fully 
understood, but a great deal of recent work has been done 
(78,83,84,99,100,107-113). 
1.5.1 Fluid Mechanical Effects on Milk Coagulation 
In contrast to the great volume of literature on the 
effects of fluid mechanical phenomena on blood 
coagulation, little has been written on the effects of 
the same phenomena on milk coagulation. 
Agitation, particularly in the presence of air, and 
homogenization in which milk is forced through small 
passages under pressure (e. g. 2000 psi) at velocities 
of approximately 600 ft/sec, both result in the 
breakdown of the fat globules. This results in the 
formation of smaller globules whose membrane is of 
different. composition to the original. As well as 
causing smaller globules to be formed, agitation can 
cause the release of free fat into the plasma, and 
aggregates of fat globules to be formed (114). 
The destruction of the original fat globule membrane 
allows enzymes, such as lipase, to attack the fat causing 
lipolysis (115-117), which is an enzymatic digestion of 
the fat to give free fatty acids, which will inhibit the 
action of rennin. However, homogenization or agitation 
will hasten coagulation, in spite of the decreased rennin 
activity, although the firmness of the milk curd formed 
will be reduced (224). 
It seems probable that fluid mechanical phenomena will 
have the same effect on the deposition of milk as they do 
on blood. However, to establish that this is the case, 
a series of experiments have been performed. These are 
described later and the results obtained suggest that the 
analogy does, in fact, hold. 
1.6 Blood Coagulation 
There are two distinct types of blood coagulation: - 
haemostasis and thrombosis. Haemostasis occurs in 
stationary blood and is the "normal" coagulation (118). 
Thrombosis is the deposition of blood constituents from 
flowing blood, and is not equivalent to haemostasis, but 
is a distortion of the haemostatic process. 
1.6.1 Haemostasis 
Several biochemically orientated reviews of the clotting 
factors invlved in blood coagulation have appeared in 
recent years (119-121). A 13 factor cascade mechanism 
has been postulated comprising two separate pathways, 
the intrinsic and extrinsic systems. 
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Figure 4. Cascade Mechanism of Blood Coagulation 
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The intrinsic pathway involves only blood factors, whereas 
the extrinsic pathway requires the participation of a 
tissue lipoprotein (tissue factor). The pathways converge 
at the level of activation of factor X. The operation of 
both seems hecessary for effective haemostasis; deficiencies 
of factors in either result in a haemorrhagic state. 
Common name Molecular weight, 
" 
_Concentration 
in I ml plalima 
Factor I Fibrinobmn 340000 (330000) 3 mg Factor 11 Prothrombin 72000 (38 000) 200 pg Factor III 
_Tissue 
factor 220000-- 320000 0 
Factor IV Calcium ions - _ Factor V"". Proacceltnn 
f 290 000 1 400 0( 7 actor VI Activated V 
Factor VII Proconvertiri 63000 (63000) 2µg 
Factor VIII Antihacinophilic factor 7 7 
Factor. 1X Christmas factor 55400 "(46500) 3-4µg 
Factor X Stuart f4etor 55000 (40000) 6-8 µg Factor XI Plasma thromboplastin antecedent 160000 (160000) 7 ig Factor XII Hageman factor 90000 (90000) 40µg 
Factor XIII Fibrin stabilizing factor 320000 (140000) 
Prckallikrein - 83000 (88000) 25-40µg 
High molecular weight kininogen 160000 80µg 
-Protein C 62000 (60000) 5g Protein S 69000 
von Willebrand factor > 1.5 million 7 pg 
Molecular weight on activated form gi%cn in parentheses. 
Figure 5. Blood Clotting Factors. 
Many of the reactions share a requirement for phospholipids 
and Ca 
2+ for rapid reaction rates. Tissue factor probably 
provides the lipid for the extrinsic pathway, and platelets 
supply the phospholipid for the intrinsic pathway (10,39). 
The phospholipid is thought to play an important part in 
organising and localizing the participants in the reactions 
(122), and also by preventing inactivation of the factors 
by naturally occurring inhibitors in plasma (123). The 
rate of conversion of prothrombin to thrombin is increased 
five hundred times by the presence of phospholipid. 
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1.6.2 Fibrinolysis 
The reverse process to blood coagulation is known as 
fibrinolysis, which causes the dissolution of a clot by 
the degradation of fibrin to water-soluble fibrin 
degradation products. This hydrolysis is accomplished 
by a serine protease, plasmin, which is generated from 
its zymogen, plasminogen, by substances termed 
plasminogen activators, which are present in many body 
fluids and tissues. Factbr XXII plays a role in 
initiating fibrinolysis and recent studies show that this 
activity may be activated by kallikrein (124). 
The existence of fibrinolysis is important with 
prosthetic implant devices for it means that if a clot 
forms, for example on a heart valve, it will not remain 
in situ indefinitely, but will eventually dislodge and 
enter the circulation. 
1.6.3 Thrombosis 
Much has been written about thrombosis over the past few 
years (12,14-16,33,39,45,125-128). Petschek's 
group (33) have done much work on the sequence of thrombus 
formation, using their stagnation point flow chambers 
(see later). The sequence of thrombus formation in this 
particular flow system, in which a jet of fresh arterial 
blood was made to impinge normally on a plane surface, 
was found to be as follows: - 
1) Within J-1 minute a protein layer is deposited 
evenly over the surface (129). 
2) This is followed by the formation of a monolayer of 
platelets (126). 
3) If a high flow rate exists over the surface, no 
further development takes place for periods of up 
to 3 hours, or, thrombus may form and grow on local 
imperfections, leading to wedge thrombi. 
4) Under conditions of low flow, a white cell circle of 
shear limited radius, centred on the stagnation 
point, is formed. 
5) Symmetric thrombi may form in the centre of the 
stagnation area. 
Thus the sequence of deposition onto a prosthetic device 
would be: - 
a) Protein layer deposition, which occurs in all cases 
independent of material. 
b) Platelet adhesion, which occurs in all cases 
independent of material. 
c) White cell deposition in areas of low flow, or on 
thrombogenic materials. 
d) Thrombus growth in areas of low flow and on 
thrombogenic materials. 
The thrombus growth will be similar to the blood 
coagulation mechanism described above. 
1.7 Comparison Between Milk and Blood Clotting 
Proteolysis seems to be the triggering mechanism for both 
clotting reactions, and is generally casued by the action 
of thrombin on the fibrinogen in blood and of chymosin on 
the casein in milk. The presence of Ca2+ enhances the 
final stage polymerisation in both cases. Both reactions 
have similar kinetics (100), are favoured by the same 
temperature effects, and mechanical effects may cause 
aggregation in both cases (80,114). Although the membranes 
of the fat globule and the milk micelle are much thinner 
than that of the blood cells, it may be possible to obtain 
a meaningful analogue for haemolysis in blood (115,116, 
80). 
Perhaps the greatest difference between the clotting of 
milk and blood is that all the reactants required for the 
coagulation of blood are present in the fluid, whereas 
the clotting agent for milk (chymosin) is in the stomach 
of the natural recipient (119,130). 
Several experiments have already been performed comparing 
the coagulation of milk and blood, and there are others 
in which the technique used for the milk tests is 
sufficiently similar to one used for blood, that the results 
are comparable. 
The experiments of Gott (45) and Berridge (79), in which, 
rings of different materials are implanted in the venous 
circulation, and clotting milk flows over the strips of 
different materials respectively, demonstrate the importance 
of surface chemistry (Virchow's triad) in coagulation. 
The effect of coating the surface of a milk test piece with 
lecithin is very similar to the effect of coating a Gott 
ring, for use in blood, with heparin, and the suggestion 
that the protection they afford surfaces'is due to a 
delay in the absorption of proteins, is tenable in both 
cases. 
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Stainless steel 2 10 
Other metals 3 20 
Soft paraffin 4 4 
Hard paraffin 2 5 
PTFE 2 6 
Cholesterol 3 3 
Aorta 3 16 
Polyacrylamide 4 8 
Collodion 4 5 
Lecithin 1 2 
lecithin and cholesterol .6 3 Agar 
.5 3 Starch 
.3 5 Cellulose membrane on 
stainless steel .2 2 Wood 
. 06 . 06 Cellulose membrane con- 
taining CaCI3 13 13 
Cellulose membrane con- 
taining paraffin 2 2 
Cellulose membrane con- 
taining EDTA . 00 . 00 
Figure 7. The rate of deposition of curd from rennetized 
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Minutes 
Weight of curd adhering to a stainless steel 
strip; " covered with lecithin. 0 with an equimolar 
mixture of lecithin and cholesterol. Dotted lines from 
Fig. 3. 
Figure 8. The process c 
surfaces. 
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30 60 90 120 150 
Minutes 
The effect of various hydrophobic materi- 
als on stainless steel. 0 cholesterol. - " polytctrafluor- - 
ethylene, a hard paraffin mixture, " soft paraffin 
("Va cline"). 
f deposition of curd to various 
The growth of milk curd, on the surface, found by 
Berridge is not steady in all cases. The solid can be 
dislodged in a manner similar to that of an embolus being 
"thrown off" in a blood system. The result for milk 
curd on wood is very. interesting and an investigation as 
to whether wood is also athrombogenic would be justified. 
Payens (100,112,113) has analysed the kinetics of the 
clotting of milk and blood. He has shown that the lag 
phase in the clotting is due to the difference in reaction 
order of enzymatic production and flocculation, instead of 
being due to the need for the substrate to have been 
completely modified before flocculation can begin (99). 
He finds that the condition for the clotting time is 
t/ksV/2 =C where t is the clotting time, ks the 
flocculation rate constant, V the maximum rate of 
enzymatic product formation and Ca constant. Double 
logarithmic plots of t versus enzyme dilution are always 
observed to be linear over a wide range of enzyme 













Figure 9. Typical examples of the regression of log 
clotting time on log enzyme dilution. (A) The clotting of 
citrated horse plasma by thrombin. (B) The clotting of 
milk by rennet. 
º log Ic1; 'arbilnry units 
log 10'; lrbllnry units 
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Substrata Enzyme prep. Slope R2 
a) Number 
of-cxps. 




)Iasma chicken embryon. extract 0.41 - - 
blood pltsma chicken embryon. extract 0.50 - - 
blood plasma chicken embryon. extract 0.68 - - 
blood plasma thromboplastin 1.08 0.999 
4 
citnted horse plasma thrombin 0.73 
0.967 9 
human fibrinogen human thrombin 1.0 - - 
milk calf rennet 
0.77 0.998 18 
milk calf rennet 
0.95 0.999 16 
mi. YUlr casein calf rennet 0.99 -0.976 
5 
,, {sein calf chymosin 
0.87 0.987 4 
r. casein M. PusiUus protease 
0.83 0.992 4 
Figure 10. Double logarithmic regression of clotting time 
versus enzyme dilution observed with the clotting of blood 
and milk. 
Sinitsina and Palmin (131) studied the effect of salt 
solution soluble and water soluble proteases, isolated 
from leucocytes, upon milk. They found that the water 
soluble fraction was capable of clotting milk and raised 
the rennin activity, whereas the salt solution soluble 
fraction did not clot milk and tended to inhibit the 
action of rennin on the milk. They concluded with the 
supposition that the salt solution soluble fraction of 
leucocyte proteases are in their action closely related 
to trypsin, which does not clot milk, whereas the water 
soluble fraction, which does clot milk, resembles chymosin. 
They do not mention whether these fractions are capable 
of clotting blood, nor indeed do they identify which 
proteases they have dissolved. Nevertheless, that it 
should be possible to clot milk with an extract of blood 
so simply obtained, suggests a possible parallel between 
the clotting processes in milk and blood. 
_ ý8 
That the two fluids are genetically related is supported 
by work done by Fiat et al (132), who found that there is 
an immunological cross reactivity between bovine fibrinogen 
and bovine k-casein. 
In the U-tube gelometer experiment described by Scott- 
Blair (80), pressure is applied alternately to one side 
and the other in a U-tube containing clotted fluid and 










20 30L 40.50 
Time I (min), from instant of addition of coagulating agent 
Figure 11. Plots of Logistic Equation for coagulation of 
milk by rennet and blood by plasma geloplastin. 
This experiment was originally used in a comparison 
between milk and blood, and shows the "general similarity 
of behaviour in the rheological properties of bovine 
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blood coagulated by plasma geloplastin and of milk 
coagulated by rennin". This result is important because, 
as has been pointed out above, one of the desirable 
properties of a blood analogue is that, as well as clotting 
in a way similar to that of blood, it should behave 
analogously once it has clotted. 
Conclusions 
Milk and blood are in many respects very different fluids. 
Blood, with its platelets, erythrocytes and leucocytes, 
and containing all the reactants required to activate the 
clotting mechanism within these cells and the plasma, 
is a much more complex fluid than milk. Milk has micelles 
and fat globules, which like the blood cells both have 
membranes. The fat globules can aggregate under agitation 
as can the platelets in blood. The size range of the fat 
globules in whole milk is from 0.1 -6 microns, whereas 
the platelets are roughly 1 micron. 
The protein involved in milk coagulation is k-casein and 
the final stage of the rennin action is: - 
k-casein 
chymosin 
para-k-casein + caseino(glyco)peptide 
(insolbule) (soluble) 
The main protein involved in blood coagulation is 
fibrinogen and the final stage of thrombin action is: - 
Fibrinogen 
thrombin Fibrin gel + fibrinopeptides 
(insoluble) (soluble) 
Both reactions occur significantly faster in the presence 
of calcium ions. In a situation in which the blood clotting 
reaction has already been activated, i. e. if the blood has 
become hypercoagulable due to the clotting agents being 
Wir. - - 301- 
released into the blood stream, the clotting reactions 
are very similar. Likewise, as will be shown later, if 
thrombosis similar to that studied by Petschek et al 
(12) is occurring the analogy holds. However, milk 
cannot be used to predict how the blood chemistry will be 
modified by a hydrodynamic disturbance, e. g. whether or 
not the presence of a heart valve will cause a state of 
hypercoagulability, and it is unlikely that it will be 
possible to use the milk analogue for testing the effects 
of different surface chemistry. If these limitations 
are borne in mind, there appears to be sufficient 
similarity between milk and blood, for milk to be used 
for predicting the flow related thrombogenicity of 
artificial implant devices. 
1.8 Choice of Experimental Procedure 
There is a wealth of published techniques for the 
investigation of blood coagulation (12,13,17,24,27 
31,40,42,45 - 48,80,133 - 138), and the procedure 
adopted for trying to establish the milk anaolgue is the 
repetition of a sample of techniques, using rennetized 
milk instead of blood and comparing the results obtained. 
Some of these require specialised pieces of equipment, 
such as a cone and plate viscometer (17,24,138), or a 
thrombelastograph (47,48), which were not readily 
available and could, therefore, be discounted as possible 
techniques. With others, such as the Gott ring experiments 
(40,45,46) similar experiments have already been 
performed using rennetized milk and there is little to 
be gained by repeating them (79). Others would be very 
difficult to repeat with milk or would give results which 
would be difficult to interpret (12,13,27,47,135). 
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The Lee White test tube study (139) is a very simple 
experiment, which consists of taking one ml. of blood 
from a vein and placing it in a small glass test tube 
(8 mm diameter). The tube is rotated endwise every 30 
seconds, and the endpoint is marked when the blood no longer 
flows. This experiment is easily duplicated using a 
milk-rennet-CaC12 mixture and was used to find the desired 
concentrations of rennet and calcium chloride and the 
optimum temperature for uses in the early stagnation 
point flow experiments described later, using a clotting 
time of 5 rains. In this experiment the milk with 1% conc. 
CaCl 2 solution and 1% rennet essence at room temperature, 
behaves in a manner analogous to that of blood, the milk 
ceasing to flow after. it'has clotted, with a. reasonably 
sharp endpoint., 
The two main experiments chosen totest`the extent of the 
analogy between the coagulation characteristics of'flowing 
blood and those of a milk mixture having the'same"Lee-White 
, clotting behaviour, were Petschek's Stagnation Point Flow 
Experiment: (11) and Hladovec's Net Experiment (140). 
In the stagnation point flow experiment blood or rennetized 
milk impinges normally onto a glass slide, and the patterns 
of deposition occurring at and around the stagnation point 
are observed. In the net experiment the pressure variation 
upstream of a net attached to the end of a tube through 
which coagulating blood/milk flows is continuously 
monitored. 
CHAPTER 2 
THE STAGNATION POINT FLOW EXPERIMENT 
2.1 Introduction 
This technique isolates the hydrodynamic and chemical 
factors controlling clotting on foreifrn surface; 
Fig 12. Photograph of per: opex flow chamber u: oed for 
milk deposition studies. 
A jet of fresh arterial canine blood impinges normally on 
the flat surface under test, which forms an end wall of 
a closed flat cylindircal chamber coaxial with the jet. 
Surface deposits are examined microscopically in situ 
when the specimen is transparent. The system operates 
completely full of blood, the , spent fluid being withdrawn 
at a controlled rate from the perimeter of the chamber at 
a point sufficiently far from the axis so as not to disturb 
the symmetry of the flow near the stagnation point. In 
studies of the effects of changes in nature of the test 
surface and the flow conditions, many patterns of deposition 
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phenomena occur. 
The sequence of these can be summarized as follws: - 
1) Initial deposition of a layer of protein over the 
entire surface. This occurs very quickly and 
Leininger (141) suggests that, for plastics, the 
normally negative charge is then lost. 
2) A monolayer of platelets is deposited in an 
apparently random manner over the surface. 
3) The platelets may aggregate into "clumps" randomly 
over the surface and/or white cells may be 
deposited in a circular configuration. 
4) Thrombi may grow on the surface either symmetrically 
around the stagnation point or in wedge shaped 
deposits downstream of surface imperfections. 
2.2 Fluid Mechanics 
The formation of a white cell circle of limited radius 
diminishing with increasing flow is explained by Petschek 
et al in terms of a supposed radial distribution of 
shear stress. 
T=pvr 
where T is the shear stress 
p is the density of blood 
is an empirically determined flow parameter 
characterizing each of the flow chambers used 
v is the kinematic viscosity of blood 
and r is the radial distance measured from the central 
streamline. 
Thus, for a given flow parameter, ß , the shear rate should 
be zero at the stagnation point, and would appear to increase 
linearly as the fluid moves radially outward. The boundary 
-- 
of the white cell circle is from this viewpoint, at the 
radius where the shear stress has a value sufficient, 
to overcome the adhesion bond between the white cells 
and the surface. 
An investigation of the fluid mechanics of the chamber 
flow, using the laser holographic technique developed 
in this laboratory (142) to measure mass transfer 
coefficients, has shown that the shear stress rises radially 
outwards within the inner impingement zone according to 
the above equation but that outside the jet orifice area 
shear stress falls off with increasing radius (55,56). 
Thus the analysis by Petschek et al holds only within the 
jet region and fails to explain those white cell circles 
which are of diameter greater than that of the jet. It 
is possible that the deposition of white cells is indeed 
limited by shear stress, but, blood is not a continuum 
and one explanation of those circles may be that the 
fluid shear acts on the particles or cells attached to 
the surface and although the force may be insufficient 
to pull them completely away from the surface, it is 
sufficient to drag them radially outwards until the fluid 
shear force is equal to the tangential adhesive force 
between the cells and the surface. Furthermore, since the 
particles being dragged along the surface will have acquired 
momentum, if their density is greater than that of the 
bulk fluid, they may not come to rest until some distance 
beyond the point at which the fluid force balances the 
tangential adhesion force. Thus it is possible to obtain 
shear limited circles whose radius is such that the perimeter 
is outwith the range of rising shear stress but into the 
region of diminishing shear stress. 
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2.3 Milk Experiments 
Three chambers similar to those used by Petschek et al 
were constructed in perspex. Petschek had used seven 
flow chambers with five different /3 values. Each value for 
p was determined empirically, and gives a measure of the 
shear in the chamber. P is a function of the chamber 
depth and the diameter of the inlet hole. 
Chamber ß, (mm-src)-t Suplu. rt llcight, 
b. rnm 
Entrance Ilula 
Uirmctcr, J, m. 1t 
A 2.9 B 1.9 1.9 2.9 ( 8.6 0.69 2.9 ll 17 0.31 2.5 
157 0.20 1.6 
157 0.20 1. G ýý 2(X) 010 12 
Fig 13. Flow Parameter p and dimensions for Petschek's 
flow chambers. 
In order to give a range of shear the dimensions of 
chambers A, D and E were used giving p values of 2,17 
and 157 respectively. 
The milk was pumped into the chambers using Meltec D. N. 
Infusion pumps. These are variable speed screw drive 
syringe pumps capable of pumping between 0.13m1/hr and 
133.3m1/hr per 50m1 syringe. In order to give the 
2ml/min which Petschek et al had used, two syringes were 
filled with milk and connected to one of the two pumps 
used, which was usually set to 66.65ml/hr giving a milk 
flow rate of 133.3m1/hr and a run time of up to 45 mins. 
The two syringes on the other pump were filled with rennet 
essence and a saturated solution of CaCl 2 respectively. 
The rennet essence used was a standard cheese-making 
preparation containing the enzyme chymosin, sodium chloride 
and sodium benzoate. 
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The liquids were pumped down separate tubes and were 
introduced through hypodermic needles to'a piece of 
flexible tubing connected to the inlet to the chamber. 
Small bore needles were used to improve mixing, which 
Rennet 
1.33m] 
was a problem with the very small flows used. 
m 
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Fig 14. Arrangement used to obtain good mixing. 
The pumps and syringes were placed in a thermostatically 
controlled oven set to the temperature required for each 
run. The chambers were placed on the stage of a Zeiss 
photomicroscope so that continual observation of the 
underside of the coverslips on which the milk was 
impinging was possible. Thin slides were required to 
allow continuous observation and Chance Propper No 1 
24 x 50mm microscope glass cover slips were found to be 
sufficiently thin. Unfortunately the thin glass slides 
were very easy to break and great care had to be taken 
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2.4 Results 
The first step in the sequence of deposition with milk 
appears to be protein layer adsorption. This is largely 
conjectural, but observation of the surface under 
800-900 magnification reveals a deposit over the entire 





.. ýýc' 'M v 
i 
IL ON 
Fig 16. Milk. Slide surface outside stagnation point 
after run. Standard chamber has hole diameter of 2,5mm 
and a distance of 0.31mm between the chamber column and 
the slide giving a )3 value of 17(mm sec)- The milk 
flow rate is 2ml/min throughout and rennet and cone 
CaC12 solution are both added to 1% by volume. The run 
duration was 5 minutes and the temperature 380C. 
Magnification 840x. 
Subsequently there is a deposition of small particles 
onto the surface 
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A :1 
Fig 17. Milk. Slide surface at stagnation point. Low shear chamber wiýh 
hole diameter 2.9mm and depth 1.9mm giving aA value of 1.9 (mm sec) 
A low temperature of 15°C and a low CaCl2 concentration were used. 
Run Duration 30 minutes. Magnification 135x. 
This parrallels Petschek's platelet monlayer deposition which was found 
with blood. 
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Fig 18. Blood. (Avco Everett Research Laboratory). A similar deposition 
pattern to that shown for milk in Fig 17 onto a LT1 carbon disc in a 
chamber ofýi-value 31(mm sec)-1 after 30 minutes. Magnification 115x. 
This may be followed by a deposition of larger particles similar to 
Petschek's white cell circles. 
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Fig 19. Milk. High shear chamber Iwith hole diameter i. bmm, and 
depth 0.2 mm 
giving aA -value of 157(mm seS) . Deposition at stagnation point after 





;, ter RL . ý" 
. ýi, 
" ;(Cf. '} ý' 
- +. ý. 
' Y. ý ý= 1`ýº ä. iß 
ýi 
"i, '" t 
,, 1 
,. ý"`. \i'/}. 
ýý{! "_; Vý 
" 
". ""t" . 
`. 
" r. y ",. 
S <ý. 
"` ý. ,.. ' 
S' 
. 
_%" ."1. ß r` 
" .. 
Fig 20. blood. (Avco Everett Ressear(L Laboratory). A similar deposition 
pattern to that shown for milk in Fig 19gnto an ion plated carbon 
slide in a chamber of 4-value 31(mm sec) after 30 minutes. This is 
referred to as a diffuse white cell circle. Magnification 120x. 
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This may be followed by a further deposition of larger particles 
to give a well established circle. 
111. 
I 
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Fig 21. Milk. Stagnation point deposition in standard chamber at 
250C after 30 minutes. Magnification 270x. 
ty "u 
cY "" 
Fig 22. Blood(Avco Everett Research Laboratory). A circular dupoc, ition 
pattern at stagnation point on an LT1 carbon disc in a chamber with 
value 2.8 (mm sec) -1 after 30 minutes. Magnification 270x. 
S-s 
Alternatively, it is possible to observe a phenomenon similar 
to the start, of a wedge thrombus. 
I. 
Fig 23. Milk. Deposition near stagnation point in standard chamber, 
at 38°C after 1 minute. Magnification 135x. 
, 
1,10 
Fig 24. Milk. Wedge type depositions in stagnation point region at 
30°C after 30 minutes in standard chamber. Magnification 135x. 
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ion-plated carbon slide in a chamber of value 11 (mm sec)-I after 
30 minutes. Magnification 120x. 
Fig 26. Blood. (Avco Everett Research Laboratory). Wedge thrombus near 
stagnation point on C2H2; N2/H20 glow discharge polymer. p- Value 
175 (mm sec)-1 after 30 minutes. Magnification 150x. 
With favourable conditions a calcium growth is possible 
forming a clot. 
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Fig 27. Milk. Stagnation point clot after ý, minute run at 38°C in 
standard chamber. Magnification 135x. 
asymetric thrombus around stagnation point, on LT1 carbon disc in a 























Fig 29. Milk. Stagnation point clot at 30°C after 30 minutes in 
standard chamber. Magnification 40x. 
Eig du. blood. (Avco Everett Research Laboratory). ymmutric thrombus 
around stagnation point on segmented polyurethane after 20 minutes. 
Magnification 65x. 
There are two distinct shapes of final clot possible. The 
symmetric clot 
Fig 31. Milk. Large stagnation point clot in standard chamber at 
380C after 5 minutes. Magnification 10x. 
L-. 
Fig 31 (b). Blood. Large symmetric clot from Petschek (11). 
/. 0 
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and the wedge type clot. 
r i: ;ý. Milk . Lark wed t! (2 type p lot in ý turýýara , k; <. r!, b, r 01 ý' .:. 
týr 
20 minutes. Magnification 7x. 
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A histological examination of the deposit done by Dr A 
Busuttil, a consultant pathologist at the Western General 
Hospital, Edinburgh has shownthat, for milk, in all cases of 
deposition, fat is present, but that only in the final case 
is calcium involved. 
Effect of Shear Stress 
During the experiments, it was found that with the low shear 
chamber any clot tended to form on the part of the chamber 
surrounding the entrance hole, rather than on the glass slides. 
With the high shear chamber very little deposition was found, 
paralleling the observations of Petschek et al. 
The best chamber for deposition and the chamber used for most 
experiments was the medium shear chamber. 
2.5 Discussion 
It is remarkable that rennetized milk should give rise to very 
similar microscopic effects to those observed with blood. The 
sequence of events in deposition from the wall jet in Petschek's 
flow chamber would appear to be the same for both; the smallest 
particles deposit first, followed by the larger ones and by a 
calcium growth if the conditions are favourable. 
General explanations of such phenomena-may be given in very 
simple fluid mechanical terms. Thus, in the boundary layer 
flow in the region of a wall, it is easy to show that small 
rigid particles adhering to a wall require a higher mainstream 
fluid velocity for detachment than do larger particles of 
similar shape and the same force of adhesion per unit area of 
wall contact. It is likewise plausible to suppose that small 
particles, once deposited on the way, may modify the boundary 
layer downstream in such a way as to permit progressive 
retention or aggregation of increasingly larger adherent solid 
masses in their wake. In support of such a direct physical 
account, there is a broad correspondence, as Petschek and his 
co-workers pointed out, between the distribution and type of 
deposit formed on the foreign surfaces over much of the flow 
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field in his experiments, and the shear stress distribution 
in the fluid stream. The same correspondence is revealed in 
this experiment with rennetized milk in similar apparatus. 
Whilst it may be argued that such crude mechanical 
explanations are unduly simplistic in relation to the clotting 
behaviour of a fluid as complex and biologically active as 
blood, it must be pointed out that those formed elements of 
blood which are apparently principally concerned with the 
early stages of clotting - the platelets (10,39,13,14) 
are not, in the strict biological sense, cells, having no nuclei; 
and, indeed, the same is true of the red corpuscles of 
mammalian blood. To that extent, their interactions and 
functional behaviour in forming thrombi in a flowing stream 
are likely to be simpler, and more fully describable in terms 
of external mechanical influences, than is common in 
biological systems. 
Nevertheless, it is clear that clot deposition is not related 
to fluid shear stress effects in a suspension of minute 
rigid particles in a simple fashion; in particular it has been 
shown (56) that the pattern of deposition in Petschek's 
experiments is not exactly related to the distribution of 
local shear stress in all parts of the field of observation. 
This consideration, however, does not bear directly on the 
present question; viz whether, or to what extent, the same 
local fluid flow factors promote clotting on foreign surfaces 
exposed either to blood or rennetized milk. It must be borne in 
mind that milk, like blood, is a complex biological system 
composed of structured and differentiated functional elements, 
part, at least, of whose role is apparently to form a coagulum, 
when brought into the presence of the appropriate enzyme; 
i. e. the rennet in the natural recipient's stomach. Whatever 
the factors which complicate and modify the relationship 
between shear stress and clot deposition in Petschek's blood 
chamber experiments, it is noteworthy that the identical 
distribution of deposition is found in the flow chamber 
experiments with milk. 
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The constraints governing the design of the experiments by 
Petschek were different from those with milk. They 
designed the chamber to have a very low flow rate (2m1/min) 
in order to maintain each run for an acceptable period 
(30 minutes) before the loss of blood began to affect the 
animal. This low flow rate makes the use of the chambers with 
milk very unsatisfactory because of the problem of mixing 
three streams, two of which have only 1% of the flow of the 
other, immediately prior to the chamber. It was decided 
that in order to mimic Fetschek's work the same size of 
chamber and flows must be used to avoid diverse effects 
which were not present in his experiments, but unfortunately 
no real answer to the mixing problem was found. The tubes 
involved were 3mm diameter and the inclusion of narrowings 
in the tube tended merely to cause clogging. It was 
decided that the next experiment tried should be on a larger 
scale so as to remove the problems of dealing with flows of 
only 0.02 ml/min and should be an experiment which would 
yield results on the macroscopic level to complement the 
excellent results already obtained using the stagnation 
point flow experiment. The most promising published 
experiment seemed to be Hladovec's Net Experiment (140). 
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CHAPTER 3 
THE NET EXPERIMENT (140) 
3.1 Hladovec's Experiments 
The purpose of this experiment was to simulate the 
development of a thrombus in vitro, based on the assumption 
that it is necessary to form a favoured site where thrombus 
is produced from circulating blood. It was also desired 
to continuously register the process of its formation. 
The experimental arrangement is shown in figure 33. 
PERISTALTIC 
PUMP 




Fig 33. Experimental Arrangement from Hladovec (140) 
A 50cm length of 3mm i. d. polythene tubing was connected 
to a small peristaltic pump and onto one end of the tube 
a 0.25, mesh nylon net was attached. Both the ends of 
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the tube were placed into a 3.5m1 siliconized glass 
cuvette and the pressure upstream of the net was 
continuously recorded. The thrombus formation took 
place downstream of the net and it was this growth of 
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Fig 34. Net Fixation and Location of Thrombus (140). 
The flow rate round the system was 55ml/min and the total 
volume of fluid in the system was 7.5m1. Human or rat 
blood was collected and was citrated to the extent of 
1ml disodium citrate 3.8% to 9m1 blood. At the beginning 
of each experiment the blood or plasma was recalcified 
using CaC12. Whole blood, platelet poor plasma and 
platelet rich plasma were used in the experiments, which 
were conducted at room temperature. 












1) The thrombus formation took place behind the net 
instead of in front of it as would be normal in 
filtration. 
2) The time to formation of thrombus shortened with 
rising temperature. 
3) Thrombus formation times were not affected by 
mesh size and diameter of tubing. 
4) In the proximity of the mesh he found scattered 
islets of granular platelet masses with an 
increasing amount of fibrin and erythrocytes in the 
direction of flow. 
5) There were three phases of thrombus formation: no change of 
pressure was observed in the first phase, 
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Fig 35. Pressure Curves-found by Hiadovec. A. B. C., 
represent Separate Phases of Thrombus Formation. 
In order to duplicate Haldovec's work the following 
apparatus was used. 
Wilk Experimental Procedure 
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A Shuco pericyclic pump was used to pump milk around 
the circuit at 75m1/min. The circuit comprised: a 
10ml glass cuvette, a length of 3mm i. d. silicone 
tubing and a perspex T piece into the side arm of which 
a Gaeltech series 3EA minature strain gauge pressure 
transducer was attached. The pressure transducer was 
connected to a servoscribe chart recorder so that 
continuous recording of the process was possible. 
Attached to the end of the T piece was a short piece of 
silicone tubing with the mesh attached. 
Metallic mesh which was donated by United Wire was 
normally used; a circular piece was obtained using a 
4" punch and was then glued to the end of the tubing 
using evo-stick. This was found to be very satisfactory 
as a good seal could be obtained which would, however, 
break before the pressure in the system, due to the clot 
in the mesh, became sufficiently high to damage the 
pressure transducer. A new filter was used for each run. 
10cc of milk was filled into the glass cuvette, which was 
then heated to the temperature required for the experiment. 
Both ends of the tubing were then introduced into the 
cuvette and circulation began. Rennet essence and CaCl 2 
solution were added through hypodermic needles from 
1cc syringes and the chart recorder switched on. The endpoint 
was taken as being when a pressure rise of roughly 30mm Hg 
had occurred. The pump was then stopped and the system 
cleaned using Tergazyme, an enzymatic detergent, before 
the next run began. The cleaning fluid at 50°C was pumped 
round the circuit for roughly 15 minutes followed by 3 
separate washings with clean water. Saturated calcium 
chloride solution was used throughout and the rennet 
essence was the same as that used for the previous experiment. 
- ý) b- 
3.3 Results 
1) Clot formation took place behind the net as 
Hladovec had found with hood. 
Fig Si. Location of' Clot found with Milk 







Fig 38. Clot Formation Time vs. Temperature. 
3n 
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3) The clot formation times were not a function of 
mesh material or size, although the quantity of 
adherent clot varied from material to material; 
bronze being more prone to large clots than 
stainless steel. 






Stainless steel mesh at 40°C 1% rennet essence 
& 1% sat CaCl 2 Sol. 
Fig 39. Influence of Mesh Size on Clotting Time. 
Material flange of Mean No of 
Clotting Time Secs Readings 
Bronze 76 31 - 44 38 7 
Stainless 
Steel 76 31 - 42 35 8 
Nylon 40 - 47 43 3 
Brass 142 36 - 44 40 2 
Copper 185 42 - 43 42.5 2,. 
Fig 40. Influence of Material on Clotting Time at 
40°C and % rennet & CaCl 2 
4) Hladovec found an, increasing amount of fibrin and 
larger cells in the direction of, flow. Histological- 
examination of the deposit on the mesh revealed ý{ 
that in the whole area there-was a protein meshwork 
with trapped fat globules but towards the periphery 
59 
there were globules 4 times the size of those near 
the mesh and large clumps of a calcium deposit, 
which is similar to Hladovec's findings. 
5) The shape of the pressure rise with milk was very 
similar to that found with blood. Increasing the 
concentration of calcium chloride affected the 
shape of the curve (see Fig 42). 
ii 
i3 aß. Cý'. _ A 
Figs 41 & 42. Influence of CaCl 2 conc on Shape of 
Pressure Rise (41,1%, 42,0.5%). 
Haldovec identifies three phases and the equivalents 
for milk are marked on the figures. 
As well as being used to duplicate Hladovec's work the 
apparatus was also used to obtain the effect of temperature, 
rennet concentration and calcium chloride concentration 
on the clotting time. These, -are shown in figures-38, 
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Fig 44, Clotting Time vs CaC12 Conc. at 1% Rennet Conc. 








This proved to be a very useful and successful 
experiment; the results highlighted remarkable 
similarities between the clotting and deposition 
behaviour of rennetized milk and blood and the 
functional relationships between the clotting time and 
the temperature, rennet concentration and calcium 
chloride concentration were obtained. These relationships 
are very important and make the design of a large scale 
testing ring very much simpler. 
The observation that the clot forms behind the net for 
both milk and blood is very interesting. Normally, 
during filtration, the. cake forms on top of the filter, 
therefore, one can assume that the phenomenon occurring 
here is not a filtration. The milk or blood does not 
simply circulate until aggregates are formed which are 
larger than the holes in the mesh and then become trapped 
onto the filter. If, instead of considering the filter 
mesh as a whole, one considers a single wire, then there 
will be a stagnation area immediately downstream of the 
wire onto which small particles will adhere. Once 
particles have begun to adhere to the underside of the 
mesh the stagnation area is increased so that larger 
particles or aggregates of small particles can deposit 
"sheltered" from the flow. When the enzymatic phase of 
coagulation is completed the rate of deposition will begin 
to increase as the stickiness of the particles is increased 
and as the stagnation area is increased the effect will 
be further enhanced. 
If this argument is applied to the variation in pressure 
immediately upstream of the mesh one would expect to 
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observe; little or no pressure rise until the enzymatic 
phase is completed, for the particles will not be 
protuding into the path of the flow and thereby causing 
any restriction. 
Once the enzymatic phase is over the pressure would begin 
to rise. If the flow area available was reduced linearly 
with time, the pressure rise would be parabolic as the 
pressure w, areal. However, the rate of reduction of area 
is probably not linear but has increasing order as the 
bulk fluid coagulates so one would expect the pressure to 
begin to rise slowly as the particles begin to aggregate 
and then rise very steeply once bulk coagulation occurs. 
This would explain the three phases which Hladovec found 
and which can be identified with milk. 
If the above theory were true one would expect to find a 
variation in composition of the clot downstream of the mesh 
with the larger particles and fibrin or calcium deposit 
towards the outside of the clot, assuming the deposition 
sequence to be the same as that found in the Stagnation 
Point Flow Experiment. This is indeed the case as 
Hladovec found an increasing amount of fibrin and 
erythrocytes in the direction of flow and a histological 
examination of the milk clot found the fat globules at 
the periphery were 4 times the size of those near the 
mesh and large clumps of a calcium deposit were also present 
at the periphery. 
The clot formation times would not be expected to be 
highly dependent on material or mesh size, but, the 
value of the extended pressure rise and the extent to which 
the clot remains adherent to the mesh would be as Berridge 
(79) has shown. This was found but the range of materials 
tried was limited and no conclusions other than that the 
material affects the amount of clot can be drawn. 
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The influence of temperature on clotting time (Fig 38) 
was very marked and unfortunately there is no point on 
the graph at which a fluctuation in temperature could be 
said to have little effect. The temperature will, therefore, 
have to be carefully controlled in the full scale testing. 
The rennet and calcium chloride graphs (Figs 43,44) show 
that provided a conc. of 1% or above is used small 
fluctuations in concentration will have no great effect. 
After the success of this work it was felt that 
proceeding to the fabrication of a full scale rig for 
testing artificial heart valves was justified, as it had 
been shown that milk behaved similarly to blood 
microscopically in the Stagnation Point Flow Experiment 
and macroscopically in Hladouec's system. This work on 
the Net Experiment thus complimented the results with 
Petschek's apparatus and confirmed the analogy on the. 
macroscopic level. 




THE USE OF RENNETIZED MILK FOR TESTING THE 
THROMBOGENICITY OF HEART VALVES 
4.1 Introduction 
The use of prosthetic heart valves first began in 1952 
when Hufnagel implanted a caged ball prosthesis in the 
descending aorta (143). This prosthesis had limited 
success, but it was not until the early nineteen sixties 
that any real advance in valve replacement was made, 
although the ball valve was still the favoured design 
(3,144,145). The early models of the Starr-Edwards 
valve were beset by thromboembolic complications (146) 
and reports of ball variance (147). These complications 
led to the covering of the valve annulus and subsequently 
the cage, and the replacement of the silastic ball with a 
stellite ball. However, these modifications failed to 
solve the problems (38,148 - 154) even when patients 
were undergoing anticoagulant therapy. 
Caged disc prostheses were developed to overcome the 
problems of poppet inertia, and ventricular-prosthetic 
disproportion by reducing the length of the cage, but 
all central occluder prostheses were characterized by 
moderate to marked transvalvular gradients (155 - 160), 
which led to the development of tilting disc valves (62, 
161 - 167). The Bjork-Shiley and Lillehei Kaster valves 
have been widely used and the transvalvular gradients 
greatly reduced, but the problem of. thrombosis and -, 
thromboemolism still exists (20 - 23,, "168 - 175)..... The_ wa 
y 
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Edinburgh valve, designed to operate without 
anticoagulants, is as yet untried clinically although 
in vivo trials have been very promising (52,51,176, 
177). The assumption on which the design of the 
Edinburgh valve is based is that, if the valve has the 
optimum hydrodynamics and is made of the most athrombogenic 
materials, it will not cause thrombosis. Unlike the 
Lillehei Kaster and Bjork-Shiley valves which only open 
to 600, the Edinburgh valve is made to align fully with 
the flow by employing an aerofoil shaped pivoted occluder 
and is designed to be moulded in vitreous carbon. The 
absence of a technique for evaluation of the thrombogenicity 
of a valve has, among other things, delayed its production. 
Another solution to the problem of thrombosis and 
thromboembolism is the use of Tissue valves. Several 
types have been tried: the homograft (178,179,180), 
fasia lata (181), pericardial Xenograft (182,183) and 
the porcine Xenograft (184 - 198). These valves are 
usually associated with a low incidence of thrombosis 
and thromboembolism, but the long-term' durability is 
suspect; the expected life of the valves is only 5-7 
years. Some centres also report a fairly high incidence 
of thromboembolism (199). 
Although heart valves have been in use for nearly 30 
years the ultimate valve, with negligible thrombosis, no 
thromboembolic complications, and which will last longer 
than the normal human life span, whilst allowing the 
recipient to lead a normal healthy life, has yet to be 
found. One of the main problems the designer has had to 
face is the difficulty of ascertaining the thrombogenicity 
of a valve without extensive clinical trials, and the 
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present work is an attempt to provide a means of doing 
this in vitro using rennetized milk as an analogue of 
blood. 
4.2 Design-Criteria 
It was decided that a single pass system was required 
to reduce the problem'of circulating aggregates/clots. 
A run time of" 1 , hour- was felt to be the minimum 
acceptable, although other experiments have used 
shorter times for testing the thrombogenicity of 
materials (200). It was necessary to heat the milk to 
say 40°C before the artifical heart; and it was felt 
-'-best not to heat the bulk fluid, as, maintaining milk at 
-40°C-for one hour would cause reactions to take place 
which might-affect the results. As the temperatureýof 
the milk was to be raised the dissolved-gases which were 
in equilibrium. with the milk at room temperature would 
evolve from the liquid and somewhere these would have to 
be removed before the artificial heart., - Rennet and. calcium 
chloride` would. have tobe addedto the milk immediately 
before the heart and good-mixing obtained. -Since each 
experiment was clearly-to be fairly expensive it was" 
, 
decided to use a two'test valve artificial heart instead 
"ti of the one'test valve heart available. 
4.3 
_ .; 
: The "Apparatus fl 
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Fig 46. Flowsheet of Apparatus Used for Valve Testing. 
W 
4.3.1 Milk Storage Tank 
The milk arrives in 3x 10 gallon drums and is poured into 
a 50 gallon polypropylene tank. The tank is mounted 
in a frame on wheel to facilitate cleaning and moving 
if it becomes necessary. At one end of the tank is a 
plug for draining and at the other the outlet to the 
pump and the main apparatus. The pump is a Stuart Turner 
No 10 with a maximum flow rate of 130 gallons per hour, 
and is mounted into the frame with a power cable 
sufficiently long so as to-enable the tank to be wheeled 
to the drain in the laboratory. The pump is designed to 
pump the milk to the vacumm tank through a metric size 
14 rotameter with a valve attached and the heat exchanger. 
The valve is included so that the overflow from the 
vacumm tank and header tank can be kept' to a minimum 
so that the main milk storage will not be heated too 
rapidly. 
4.3.2 The Heat Exchanger 
A Q. V. F. glass condenser type heat exchanger No HE3 is 
used with a heat transfer area of 0.3m. The milk is 
2 
inside the coil to facilitate cleaning and hot water is 
pumped through the shell. To avoid any risk of heat 
coagulation-the heating water temperature has to be kept 
below 60°C. The water is heated in a covered tank 
containing 4x 3kw kettle heater elements, as heating 
even a stream of 3 litres/min of milk from 50C to 400C 
requires 7.5kw. The temperature in the heating tank is 
controlled by the temperature on the inlet to the vacumm 
tank by switching one of the elements on and off 
automatically using a servomex temperature controller 
type TC 201. The level in the heating tank is the minimum 
possible to cover the elements so that the response is 
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fairly rapid. It is controlled by means of an 
overflow into the sink. A thermostat is also attached 
so that if the temperature in the tank exceeds a certain 
preset level all the elements would trip. This is in case 
the elements are accidentally left on. The pump used 
for. circulating the heating water is a Stuart-Turner 
No 12 centrifugal pump with a metric No 35 Rotameter. 
4.3.3 Vacuum Tank 
From the heat exchanger the milk flows into the vacuum 
reservoir which is designed to remove the excess gases 
from the milk stream. The vessel has a diameter of 
approximately 10" and is 1ft high and in order to reduce 
the volume of fluid and improve the surface area/volume 
ratio is filled with i" ceramic balls. Approximately 
6ft of water vacuum is available and the reservoir is 
raised so that that back up in the overflow tube caused 
by this vacuum can be accommodated. The vessel is made 
of polypropylene and has a flanged top so that if 
necessary it could be opened. The vacuum line is protected 
by a calcium chloride filled cylinder to avoid excessive 
water vapour damaging the vacuum pump. 
4.3.4 The Header Tank 
From the vacuum tank the milk is pumped through a flow 
adjustment valve into a header tank. The pump used is a 
Stuart-Turner No 10. The header tank ensures that any 
gas which has not evolved in the vacuum reservoir will not 
create problems in the valve tester as the pressure there 
is. approximately Oft water. The vessel is a piece of 
3" polypropylene tubing approximately 18" in height. The 
milk flows in near the top of the vessel and out to the valve 
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tester from the bottom. There is an overflow from 
near the top to the main milk tank. The overflow from the 
vessel is restricted to a minimum by the adjustable valve 
between it and the vacuum reservoir. 
4.3.5 Rennet Essence and Calcium Chloride Addition 
The milk is sucked from the header tank by the heart and 
is split into two streams by use of aY piece. Rennet 
and calcium chloride are added separately into the 
different streams by use of Shuco pericyclic pumps. The 
addition circuits-each comprise; a1 litre flask in which 
the rennet-or calcium chloride was kept, a pericyclic 
pump, a flow-control valve, a rotameter and a Portex 
disposable manometer line. The pericyclic pumps give 'a 
.. maximum flow'rate of 100cc/min.. --By 
having the flow cut 
back by this, valve the effects-of the pulsatile flow 
from--the pericyclic,. pump and the heart pump are reduced, 
and steady flow can be'obtained. The'manometer"line was 
fitted into the side arm of aT piece inthe'main milk line. 
After. the'rennet-and calcium chloride had been added the 
flows are split again before entering the heart chambers. 
4.3.6 The Heart Chambers 
The, perspex chambers which housed'the valves under test 
were büilt. to simulate- the'variation'. in flow area of the 
'approaches to-the valve`in the human heart. (Fig 47). " 
A The equivalent-diameter. cross-sectional flow areas were 
obtained from"Weiting-; (201) who injected silicone rubber 
intQ human hearts during necropsy, "sübsequently=slicing the 
silicone impression every 2.5mm parallel to the valve 
annuli for 30mm either side of the valves, and expressing 
-- 
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Fig 47. Photo of Chambers 
-- --- --- -- -- - 
_74_ 
Fig 48. Aclüal Size Drawing of Mitral, Chamber. 
-75- 
the area of each slice as an equivalent circular 
diameter. 
The aortic chamber is described by Taylor (55) and the 
mitral'"chamber was made for this particular piece of 
work. A'drawing of the chamber is shown in Fig 48. 
The positions and angles of the inlets are based on 
physiological data obtained from Professor*G J Romanes 
of the Anatomy Department, University of Edinburgh and 
mimic those present in the heart. Having four inlets 
also helps achieve good mixing of the reactants in the 
chamber. A continuous air bleed is included at the top 
of the chamber so that any air which gets into the 
system can be removed. 
The pump used with the chambers to obtain pulsatile flow 
is Macleod's positive displacement diaphragm pump, which 
has independently variable frequency, stroke volume and 
systolic/diastolic ratio (202). 
The valves are mounted into flexible rubber mouldings to 
simulate, tosome extent the flexibility of the real heart 
and as 'a mean of sealing the chambers. °By. using wing 
nuts, on bolts quick extraction of thevalves, was possible. 
Some of the valves used in their . mountings' 
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Fig 49. Valves Used for Experiments. 
A 
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Outflow 
From the chambers the milk is pumped to a down pipe 
at a height roughly 1ft above the height in-the header 
tank. This is necessary to obtain a back pressure to 
close the valves. A stream of cold water is also 
introduced at the top of the down pipe to minimize fouling. 
The milk flows into a sink where the flow rate can be 
measured using a flask and stopwatch and thence to 
drain. 
4.3.7 Control 
All controls are manual apart from the automatic 
temperature controller. This has been found to be fairly 
satisfactory; -although computer control using a PET 
would be desirable. The temperatures on the'"inlet'to the 
heat exchanger on both the water and milk sides are 
measured as are the temperature on the outlet side (water), 
the inlet to the vacuum reservoir and the inlet to the 
header tank. Thermocouples attached to a Comark electric 
thermometer are used for all of these. The flow rates of 
the milk from the storage tank, the circulating water 
and the rennet and calcium chloride are all measured 
using rotameters. The flow rate through the heart is 
measured using a measuring flask and stopwatch, because 
the pulsatile nature of the flow does not allow the use 
of a rotameter. 
4.4 Experimental Procedure 
Before any run the-'equipment, is thoroughly' Icleaned using a 
chlorine releasing detergent (TAP)"and', then rinsed 
thoroughly with clean water. Pump and valve operation 
are checked and the pericyclic`pumps-. re checked to ensure 
that they are functioning properly as there are frequently 
problems with these. 
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The heating elements and the water circulation pump 
are switched on checking that there is sufficient water 
in the tank to cover the heating elements and avoid air 
entrainment. The water is heated to 60°C and then elements 
are switched off. 
Meanwhile, the 30 gallons of milk are poured from the 
churns into the milk storage tank adding a dye if it is 
so desired. The pump from the storage tank and the 
pump between the vacuum reservoir and the header tank 
are switched on and the flows adjusted so that there is 
only minute flow down the overflow from the vacuum 
reservoir and sufficient to allow for the flow through 
the heart pump, down the overflow from the header tank. 
The heaters are turned on and the temperature allowed 
to settle at that required for the run. 
The rennet and calcium chloride are filled into their 
containers and warmed to reduce condensation on the 
tubes of the pericyclic pumps which would impair their 
operation. 
When the temperature in the vacuum reservoir has reached 
the desired level and the flows are settled the vacuum is 
switched on. When everything is settled and ready, the 
heart pump is started and the flow adjusted to the 
desired level. The pericyclic pumps are. then switched 
on and the valves opened to give the desired flows. The 
valves are-normally kept closed to stop beackflow through 
the lines when the pumps are not working., 
1k 
A constant check is kept. on. the temperatures. and flows.. 
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When the milk storage tank is empty, after about an hour, 
the pump at the storage tank is switched off as are the 
heater elements, the water circulation pump and the 
vacuum pump. When the vacuum reservoir is empty, the 
pump between it and the header tank is switched off and 
the rennet and calcium chloride flows are stopped. The 
heart pump is then swicthed off and the overflow line removed 
from the high pipe and lowered into the sink to drain the 
system. The valves are now carefully removed from the 
chambers and placed in the freezer. 
Cleaning 
Two other valves are placed in the chambers and the whole 
system is rinsed through, with water. When all the milk 
has been rinsed out the circuit is separated into two: 
a circuit which has had no rennet through and a circuit 
which has. 
The cleaning of the circuit which has had no rennet added 
is achieved by adding T. A. P., a chlorine liberating 
detergent, to the main storage tank which is j filled 
with water. The tank is washed by hand and the rest of 
the circuit by pumping using the pumps already present. 
The overflow pipes are placed into the sink which has 
its plug in and is itself filled, allowing the water to 
drain down the sink overflow. The outlet from the header 
tank, where the first circuit ends is blocked by a 
stoppered flexible tube which is opened occasionally to 
drain and then restoppered. Once the circuit is filled 
and the cleaning fluid has circulated for roughly j hour, 
the pumps are switched off and the system left overnight 
to sterilize. 
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The second circuit which has had rennet added begins 
at the outlet from the header tank. Once the circuit 
has been rinsed through and some of the large clots 
adherent to the walls of the chamber have been removed, 
both the inlet and outlet tubes are placed in an 
elevated flask. Tegazyme, an enzymatic detergent, is 
added and the actuator is switched on to circulate the 
fluid. After it has been on for roughly j hour the pump 
is switched off and the circuit is allowed. to clean 
overnight.. 
The following morning the circuit is connected and run 
normally and the fluid flows out through the-overflow. 
When.. the, main storage tank is empty it is filled with 
hot clean water and the circuit is run to clean. `". 
Recording Results'"_". 
All valves are photogr'aphed, so'"that a permanent record,,, 
is obtained. The milk is dyed using standard, vegetable, '' 
dyes so that if a white valve is used the clots are 
clearly visible. 
Unless otherwise stated a concentration of 1% calcium * 
chloride and rennet, 30 gallons of milk and a pulse rate of 
60 - 70 were used throughout. 
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4.5 Illustrations of the Reproducibility of the Clotting 
Patterns Found Using Rennetized Milk 
4.5.1 Results 
Starr-Edwards Valve Upstream 
ýý.. 
ýýsr 
Fig 50. Starr-Edwards Aortic 
Upstream. 430C. 0.6% CaCl 2 and 
rennet. 1.7L/min milk. Pulse 50. 
Run Duration 10 mins. 
Fig 51. Starr-Edwards Aortic 
Upstream. 400 C. 2L/min milk. 
I 
/10, 
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Fig 52. Starr-Edwards Aortic 
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Fig 54. Starr Edwards Mitral Upstream. 38°C. 3L/min milk. 
Fig 53. Silicone Ball Starr-Edwards 
Aortic Upstream. 380 C. 2L/min milk. 
ý'' = ,ý 
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- _, M19A Fig 55. Starr-Edwards Aortic Downstream. Conditions as Fig 50 
r 
Fig 57. Starr-Edwards Mitral 
Downstream. 400C. 2L/min milk. 
! RF 0 
4PP. 
I Is 
Fig 56. Starr-Edwards Aortic 
Downstream. 40°C. 2L/min milk. 
Fig 58. Silicone Ball Starr-Edwards 
Aortic Downstream. 38°C. 2L/min milk. 
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Fig 59. Starr-Edwards Aortic Fig 60. Starr-Edwards Mitral 
Downstream. 38°C. 2L/min milk Downstream. 380C. 3L/mir, milk. 
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Bjork-Shiley Valve Upstream 
Fig 61. Bjork-Shiley Aortic Upstream 
40°C. 0.6% CaCl 2& rennet. 
2L/mir, 
milk. Valve albumen coated. 
_ -lam 
I 
Fig 62. Bjork-Shiley Aortic Upstream 





Fig 63. Bjork-Shiley Aortic Upstream Fig 64. Bjork-Shiley Aortic Upstream 
40°C. 2L/min milk. 40 
°C. 3L/min milk. 
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Fig 65. Bjork-Shiley Aortic 
390 C. 3L/min milk. 
Upstream F'ij 66. Bjork-Shiley Aortic Upstream 
38°C. 3L/min milk. 
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Bjork-Shiley Valve Downstream 
0 
Fig 69. Bjork-Shiley Aortic 
Downstream. 40°C. 2L/min milk. 
Fig 68. Bjork-Shiley Aortic 
Downstream. 40 °C. 2L/min milk. 
ui Fig 70. Bjork-Shiley Aortic 
Downstream. 40°C. 3L/min milk. 
Fig 67. Bjork-Shiley Aortic 
Downstream. Conditions as Fig 61. 
40 4 
-_- 





Fig 71. Bjork-Shiley Aortic Fig 72. I1jork-Shiley Aortic 
Downstream. 39°C. 3L/min milk. Downstream. 38°C. 3L/min milk. 
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4.5.2 Discussion 
Starr-Edwards Inside Ring 
The growth of a clot inside the ring of the Starr-Edwards 
ball valve occurs in all cases where any clotting is 
observed. This phenomenon is also found in the clinical 
situation as discussed earlier, and is presumably promoted 
by the presence of the ball inside the ring when the 
valve is closed. This illustrates the importants of 
transient effects in clot deposition and shows the need 
for pulsatile flow in the testing of heart valves. 
Starr-Edwards on Struts 
As discussed earlier, little or no clotting is observed 
on the struts of the Starr-Edwards ball valve in the 
clinical situation. However, when rennetized milk is used 
in vitro in all cases except Fig 60 gross clotting occurs 
on the struts, and the ball remains clear as it does 
clinically. For Fig 60 the flow rate was higher than in 
all the other cases (31/min vs 21/min) and, therefore, 
the duration of the trial was shortened, as 30ýgallons 
of milk were used in all cases: clot has, however, clearly 
begun to form. 
Bjork-Shiley on Upstream Side 
Unlike the Starr-Edwards valve the Bjork-Shiley tilting 
disc valve appears to be prone to two distinct types of 
clot deposition as discussed earlier. The first type 
is a discrete deposit forming on the struts and not 
involving the disc, and the second is a more generalized 
deposit involving the 
i; 
` ". v 
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disc as well. Fig 61 illustrates the first type and is 
different from the other runs in that the valve was 
coated with albumen prior to the commencement of the 
run. The explanation for this curious behaviour is 
not immediately obvious. However, as the coagulability 
of the milk was low due to the low concentrations of 
rennet and CaCl 2 
(0.5%) with the greater clot forming 
propensity of the valve surface due to the albumen coating, 
the clot forms at the most favourable site available, 
which may explain the discrete deposit. In the case of 
the clinical environment this is equivalent to a situation 
in which the blood has not become hypercoagulable, but 
there is some imperfection on the valve which makes a 
particular site preferentially thrombogenic. 
In the other cases the patterns are largley similar with 
clot forming over the entire surface except for the 
region which is cleaned by the struts as the valve opens 
and closes. Larger deposits also appear on the struts 
presumably at the most favourable sites, similar to those 
discussed above, but the overall impression is of 
generalized clotting. 
Bjork-Shiley on Downstream Side 
The deposition on the downstream side of the Bjork-Shiley 
valve appears very similar to that occurring on the 
upstream side. 
4.5.3 Conclusions 
These results show that the clotting phenomena observed 
on the heart valve used and in the experiental system 
described earlier, are sufficiently reproducible that 
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inordinately large numbers of runs are not required to 
test the thrombogenicity or clot fomring propensity of 
a given heart valve. 
4.6 Illustrations of the Similarities in Appearance Between 
Valvular Deposits Found with Rennetized Milk and Clinical 
Experience of Clotted Heart Valves 
4.6.1 Results 
Bjork-Shiley Valve 
Fig 73. Blood. Bjork-Shiley Downstream Fig 74. Milk. Bjork-Shiley Aortic 
After 2 Years. Courtesy MacGregor. Downstream. 400C. 0.6% CaC1 2& 
rennet. 2L/min milk. Albumen Coated. 
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Fig 75. Blood. Bjork-Shiley Upstream Fig 76. Milk. Bjork-Shiley Aortic 
Other side of' Fig 73. Upstream. Other side of Fig 74. 
Fig 77. Blood. Bjork-Shiley Upstream Fig 78. Milk. Bjork-Shiley Aortic 
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Fig 79. Blood. Bjork-Shiley Downstream Fig 80. Milk. Bjork-Shiley Aortic 
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Fig 81. Blood. Bjork-Shiley Downstream Fig 82. Milk. Bjork-Shiley Aortic 
After 6 Months. Courtesy Busuttil. Downstream. 400C. 3L/min milk 
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Fig 85. Milk. Starr-Edwards Aortic 
Upstream. 43°C. 0.6% CaCl2 & rennet. 
1.7L/min milk. After 10 Mins. 
Fig 84. Blood. Starr-Edwards Aortic 
Upstream. After 5 Years. 
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Fig 86. Blood. Starr-Edwards. After Fip; 87. Milk. Starr-Edwards Mitral 
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Fig 89. Milk. Starr-Edwards Mitral 
Downstream. 38°C. 3L/min milk. 
Fig 88. girr-E7aruL- it, ! L, 4-c. 
After 1 Month. Courtesy Stovin. 
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Fig 90. Blood. Starr-Edwards Mitral 
After 5 Years . Courtesy Stovin. 
tý _ 'ýý ý_-.. 
Fig 91. Milk. Starr-Edwards Aortic 




The ability of the rennetized milk system to mimic the 
clinical situation is well illustrated by the above 
photographs. Clinical experience of the Bjork-Shiley 
valve reveals two distinct patterns of deposition. The 
first of these involved primarily the struts and the 
sewing ring (Figs 73,75) and the second involves the 
disc, particularly the downstream side, as well (Figs 77, 
79,81). The results obtained using milk, as well as 
confirming the validity of the analogue technique, 
demonstrate that two-distinct patterns of deposition 
occur in this case also. 
Virthow (5) stated that the three predominant factors 
important in coagulation are surface chemistry, blood 
chemistry and hydrodynamics. The materials of 
construction of the valves and their preparation prior 
to implantation are the same, apart from an albumen 
coating on the valve used in the first example, which 
one would expect to lead to a more general deposit, so it 
seems unlikely that surface chemistry will be the key 
factor in causing these diverse deposition patterns. 
Since both milk and blood are prone to the same duality 
of results and the chemistry of the two fluids, although 
similar, is still very different, it would seem logical 
to assume that Virchow's blood chemistry is not the prime 
determining factor in this anomoly. However, the 
hydrodynamics of the situation for the two different 
milk results (Figs 74, '76,78,80)'are identical, the 
results being obtained in the same pulse duplicator at 
the same flow. rate'and the same pulse rate: It, 'therefore, 
seems improbable that hydrodynamics can be of 
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prime importance in this instance. The main 
difference between the two milk runs appears to be in 
the fluid Chemistry. The rennet and calcium chloride 
concentration of figures 74 and 76 were much lower than 
those for figures 78 and 80, whilst on the other hand 
the temperature for figures 74 and 76 was higher than 
that for figures 78 and 80 so that although the clotting 
times were comparable in both 'cases, the chemistry of 
the coagulation may have been rather different. In the 
case of the blood clots Effler (68) would suggest that 
the differences observed between the deposits is 
attributable to a difference in their cause. on the 
one hand the deposit covering the whole valve would be 
caused by a chemical mechanism due to the chemcials used 
in bleaching the sewing ring and the deposit adhering to 
the struts alone would be a thrombus. This may be the 
case, but it seems improbable that if it were, it would 
be possible to mimic it using rennetized milk. 
It has been proposed (8) that activation of the intrinsic 
pathway of blood coagulation results in a "hypercoagulable 
state" which leads to the formation of venous thrombi 
but does not cause disseminated intravascular coagulation. 
For example, if, in the case of the Bjork-Shiley valves, 
the intrinsic pathway had been activated in one instance, 
but not the other, this might explain the different 
phenomena occurring. If the blood has not become 
hypercoagulable, one would expect clot formation, if any, 
to be on the most thrombogenic surface present and since 
pyrolytic carbon is known to be less thrombogenic than 
stainless steel one would expect any clot to form on the 
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stainless steel struts as has been found. Stainless steel 
has also been shown to be more prone than most other 
materials to curd adhesion when coagulating milk is passed 
over it (79) and one would, therefore, expect any clot 
formation with milk to occur on the stationary steel 
struts rather than the carbon disc. It is possible, 
therefore, that a hypercoagulable state may occur in some 
heart valve implantees, and that this leads to a different 
form of deposit from that which would normally be associated 
with thrombosis. It may also be possible to mimic these 
two distinct situations using rennetized milk by varying 
the reactant concentrations and temperatures but this 
needs further investigation. 
Starr-Edwards 
The main feature of the clotting found on the Starr- 
Edwards ball valve in the clinical situation is the 
tendency for clot formation inside the sewing ring 
(Figs 84,86). This phenomenon is also found using 
rennetized milk (Figs 85,87). 
Clinical experience of the clots forming on the downstream 
side of the valve is that (a) no clots form on the ball 
and (b) some deposit is found on the struts, but appears 
to "grow" from the sewing ring. (Figs 88,90). With milk 
as with blood no clot forms on the ball, but clot does form 
onthe struts (Figs 89,91). 
The deposits on-the silicone, ball Starr-Edwards valve 
found in the clinical situation and in vitro using 
rennetized milk are very similar innature. In both 
cases it appears that clots form on the struts and are 
easily knocked off suggesting that embolization would be 
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a problem with the valve. The deposit on the cloth 
covered struts in the clinical situation appears to be 
different in nature. The cloth covered valve with a 
hollow metal ball was introduced to reduce the incidence 
of thromboembolism compared with that found with the 
silicone ball valve with bare metal struts (149,203). 
The cloth covering encourages strut encapsulation with 
autogenous tissue which apparently decreases the clotting 
propensity and explains why the degree of clot deposition 
on the struts is far greater using milk than is generally 
found in the clinical situation. However, in the period 
immediately following implantation, and before any 
encapsulation has been possible,, thrombus can form, 
similar in nature to that found with milk (Fig 88). 
Another possible explanation, for the general lack of 
large scale clots forming on the struts in the clinical 
situation is that during the cardiac cycle the struts may 
come into contact with the walls of the ventricle or 
aorta dislodging any clot which has started to form, and 
leading to thromboembol. ism which is known to be a problem 
with these valves (148,204,205). In the case of the 
mitral valve, the small end-systolic volume of the left 
ventricle of the healthy heart means that this must 
generally be true. With the aortic valve it is also 
feasible that, due to the flexibility of the heart, the 
valve comes into contact with the wall of the aorta. 
Support for this hypothesis is obtained from observation 
of photos (Figs 88,90) above. Although there are clots 
on the struts of these valves, they are situated on the 
inside of the struts, which if the hypothesis is not true 
is very suprising, as one would expect the moving ball 
to dislodge them. This indicates that the effect of the ball 
is less than that of the wall. 
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4.6.3 Conclusion 
The clots found on the Bjork-Shiley valves with milk 
are very similar to those found with blood with two 
patterns of deposition being possible in each 4' 
case. (a) a discrete deposit involving the struts and 
the sewing ring and (b) a more general deposit covering 
the disc, primarily the downstream side. 
The results of'the experiments with the Starr-Edwards 
valve are less conclusive. With both milk and blood a 
;, -deposit is found inside. the sewing ring, but, whereas 
with milk large-scale deposits are found on the struts, 
in vivo the struts remain relatively clear. This, '' 
however, may beattributable to, the, inadequacy of the 
heart simulator to mimic the heart, and it is probable 
that in'vivo clots form on the struts but are 
dislodged. 
4.7 Tests on the Clotting Propensities of Different Valves 
4.7.1 Results at 2 litres/min. 
" rnr 
Fig 94. Bjork-Shiley Aortic Upstream 
40°C 
e 
Fig 95. Bjork-Shiley Aortic Downstream 
40QC 
Fig 92. Starr-Edwards Aortic Upstream Fig 93. Starr-Edwards Aortic 
400 C. Downstream 400 C. 
ýqipl Oft 19ow 
Fig 96. Edinburgh Aortic Upstream 38 C Fig 97. Edinburgh Aortic Downstream 38C 
Fig 98. Silicone Starr-Edwards Aortic Fig 99. Silicone Starr-Edwards Aortic 
Upstream 38°C. Downstream. 38°C. 
'Air rý 
jr 
Fig 100. Flat Disc Edinburgh Mitral Fib; 101 Flat Disc Edinburgh Mitral 
Upstream,. 43°C. 0.6% CaCl 
2& rennet 
Downstream. As Fig 100. 
1.7L/min milk After 10 Mins 
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4.7.2 Discussion 
Because of the differences between the chemistry of milk 
and blood, it is not necessarily true that those surfaces 
which are known to be athrombogenic will also be 
associated with a low incidence of milk clot deposition 
and vice-versa. Therefore, to compare the clotting 
propensities of valves of different designs, ideally 
they would be constructed of the same materials. As a 
preliminary investigation, however, it is of value to 
compare the valves as used in clinical practice, since 
these are more readily available. 
All the valves tested showed tendency to clot formation 
particularly at the lower flow rate of 2 litres/min. 
2 Litres/min Milk Flow 
The flat disc valve with a pivoted occluder is a 
prototype which is not commercially available. Clot 
forms on the downstream side, whilst the upstream 
side remains relatively clear. This is due to a large 
stagnation region on the downstream side caused by the 
occluder not opening fully. 
The Starr-Edwards ball valve was consistently found to be 
prone to gross clotting on the struts and inside the 
orifice. These clots-were occasionally dislodged by the 
action of the ball, and in the clinical situation the 
clots on the outside of the struts may be dislodged by 
contact with the walls of the ventricle, in the case of 
a mitral valve, or the aorta, in the case of the aortic 
valve. The Starr-Edwards valve would, therefore, appear 
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to be potentially very dangerous due to its proneness 
to clotting and thromboembolism and very careful 
anticoagulation therapy is required. (148 - 150,203,206, 
207). 
The Bjork-Shiley valves shares with the flat disc valve 
described above the problem of stalling, and hence 
stagnation over a large region of the downstream side of 
the occluder (20). It has also the added problem of struts 
which are used to restrain the disc and these can act as 
sites for the inception and development of clots. The 
Bjork-Shiley valve was shown in these tests to be better 
than the Starr-Edwards valve or the flat disc valve, but 
the flat disc has an occluder made of delrin, whereas 
the Bjork-Shiley valve has a pyrolytic carbon occluder 
which is less prone to clot deposition. It is certainly 
possible for gross clotting to occur on the Bjork-Shiley 
valve when rennetized milk is used in vitro (Figs 94,95) 
and it would be expected that anticoagulant drugs would 
be needed in the clinincal situation as is indeed the 
case (20 - 23,169 - 173,208,209). 
The Edinburgh Valve (52,176,177) is evolved from the 
flat disc valve and incorporates an aerofoil shaped 
occluder, which enables the valve to open very nearly 
900 with the pivot axis only slightly eccentric. The 
bore of the housing is hyperboloidal or flared, the walls 
diverging slightly in the direction of flow which helps 
minimize the flow disturbance. It was hoped that 
implantation of this design of valve should not require 
the recipient to undergo anticoagulant therapy. It is, 
therefore, interesting to see how this valve compares 
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in vitro with the Bjork-Shiley and Starr Edwards valves 
which are known to require anticoagulants in vivo. 
Unfortunately, due to circumstances beyond our control, 
no valves constructed in the original specified 
material, vitreous carbon, are available and the valves 
used are, therefore, made, of delrin and stainless steel 
which are more prone to clot deposition than carbon (see 
later) (Figs 153,154). 
Despite the lack of the correct materials, the Edinburgh 
valve has been shown to be superior to the other valves 
tested; the typical pattern of deposition being an even 
covering over the entire delrin disc which did not lead 
to gross clotting in any case. 'Had vitreous carbon been 
used it is possible that the deposition might have been 
negligible. 
In the experiment in which the valve had been coated with 
albumen, the result suggests that there may be some flow 
separation on the upstream side of the leading edge and 
on the downstream side of the trailing edge (Figs 155,156). 
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Fig 155. Edinburgh Mitral Upstream 
400C. 2L/min milk. 
With the limited number of experiments performed to date, it is not 
possible to predict whether the Edinburgh valve will achieve its goal 
of not requiring the recipient to undergo anticoagulant therapy, but 
it is possible to state that on the basis of these experiments its 
in vivo performance, in terms of thrombogenicity, is likely to be better 
than the Bjork-Shiley or Starr-Edwards valves. 
Fig 156. Edinburgh Mitral Downstream 
40°C. 2L/min milk. 
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Fig 103. Edinburgh Mitral Downstream 
38°C 
dblk 
Fig 104. Bjork-ähiley Mitral Upstream Fig 105. Djork-Shiley Mitral Downstream 
C 38C 38° ° 
- 
46 1' 
Fig 102. Edinburgh Mitral Upstream 
38°C 
-ý 
ýS. riý. _ý 
ýS 
Fig 107. Starr-Edwards Mitral 
Downstream 380C 
Fig 106. Starr-Edwards Mitral 
Upstream 38 °C 
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4.7.3 Comparison at 3 Litres/min Milk Flow 
Having compared the performance of the valves at 2 litres/min, 
it is of interest to compare them at different conditions, 
and one of the main factors which may affect the clot deposition 
is the flow rate. Photographs showing typical deposition 
patterns found with the Edinburgh, the Starr-Edwards and the 
Bjork-Shiley valves are, therefore, shown above. Unfortunately 
no experiment using the Starr-Edwards valve in the aortic 
position at the flow rate has been successfully performed, 
and the photograph shown is of a valve used in the mitral site, 
which due to the nature of the rennet and CaCl 2 addition is a 
less severe test than the aortic site. This is because at the 
mitral site the rennet, CaCl 2 and milk are still mixing and 
the clotting reaction is only just beginning, whereas at the 
aortic site the milk is nearer to bulk coagulation, although 
bulk coagulation will not have occurred. 
In order to facilitate comparison, the clots on the Bjork- 
Shiley and Edinburgh valves shown were also obtained in the 
mitral position at the same temperature as used for the Starr- 
Edwards. Whereas the amount of clot on the Bjork-Shiley and 
Starr-Edwards valves is much less than found at 2 litres/min 
in the aortic site, the amount of clot found on the Edinburgh 
valve is not markedly changed. Thus, whereas at a flow rate 
of 2 litres/min the Edinburgh valve appears very much better 
than the others, at 3 litres/min it is hard to choose between 
them. It may be that at the higher flow rate more milk is 
required to allow time for gross clots to form and that the 
Edinburgh valve with its lack of favoured sites will not be 
prone to this growth. However, the coarse nature of the delrin 
discs on the Edinburgh valves used makes them very susceptible 
to an initial deposition and retention of a film of clot, even 




The differences between the materials of construction of the 
various valves make a comparison between the different 
designs very difficult. None of the valves has shown itself 
to be totally free of clot deposition, but the Edinburgh valve 
with its lack of favoured sites appears to be the most 
promising, assuming a suitable athrombogenic material of 
construction, 'such as perhaps vitreous carbon, can be used. 
0 
4.8 The Sequence of Clot Deposition 
4.8.1 Results 
Bjork-Shiley Valve Downstream 
Fig 108. Bjork-Shiley Mitral 
Downstream 390C. 3L/min milk. 
Fig 109. Bjork-Shiley Aortic 
Downstream 380 C. 3L/min milk. 
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Fig 110. Bjork-Shiley Aortic 
Downstream 400 C. 2L/min milk. 
0 
Fig 11. Bjork-Shiley Aortic 





Fig 112. Bjork-Shiley Aortic Downstream 400C 2L/min milk. 
Bjork-Shiley Valve Upstream 
.N....,. 
Fig 113. Bjork-Shiley Mitral 
Upstream 390 C. 3L/min milk. 
i 
Fig 114. Bjork-Shiley Aortic 
Upstream 38 °C. 3L/min milk. 
Fig 115. Bjork-Shiley Aortic Fig 116. Bjork-Shiley Aortic 
Upstream 40°C. 2L/min milk Upstream 39°C. 3L/min milk. 
i MIR 
'}i 
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Fig 117. Bjork-Shiley Aortic Upstream 400C. 2L/min milk. 
4.8.2 Discussion 
Using the Stagnation Point Flow Experiment described in 
Chapter 2, the sequence of milk deposition was found to be as 
follows: - 
1) Protein layer adsorption. 
2) Deposition of small particles evenly over the surface. 
3) Deposition of larger particles where stagnation occurs. 
4) Alternate to (3), larger particles can deposit at 
favoured sites. 
5) The growth of a calcium clot symmetrically if (3) has 
occurred, or in a wedge type formation if (4) has occurred. 
The sequence of deposition found when rennetized milk is passed 
over heart valves appears to be as follows: - 
1) An even and thin layer is deposited over the entire surface 
apart from those areas where rubbing action keeps the 
surface clear (Figs 108,113). 
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2) Larger scale clots form at favoured sites such as around 
the struts on the Bjork-Shiley and especially on the 
downstream side where the strut touchs the centre of the 
occluder (Figs 109,114). 
3) The thickness of the deposited clot increases (Figs 110, 
115). 
4) The deposits can become disrupted leading to greater fluid 
mechanical disturbances (Figs 111,116). 
5) Gross clot can grow affecting the performance of the valve 
and leading to obstruction (Figs 112,117). 
Presumably the first visible event of deposition on heart valves 
corresponds to (3) and (4) of the Stagnation Point Flow 
Experiment, and protein layer adsorption and deposition of small 
particles evenly over the entire surface has already occurred. 
Where the overall surface is not conducive to the deposition of 
the thin layer of clot, it is still possible to find clot 
forming at favoured sites (Figs 118,119). 
Fig 118. Bjork-Shiley Aortic Upstream Fig 119. Bjork-Shiley 
0.6% CaCl 
2& rennet. 
40°C 2L/min milk Downstream Conditions as Fig 118. 
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ý1 Irig 120. Bjork-Shiley After 2 Years 
Courtesy Stovin 
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Fig 122. Bjork-Shiley After 6 Months Fig 123. Bjork-Shiley After 2 Years. 
Courtesy Busuttil 
Fig 121. Bjork-Shiley After 6 Months 
Courtesy MacGregor 
lmiý. Ippo . OOP` 
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The probable sequence of deposition of blood on heart valves 
in vivo is shown on photographs 120 - 123. The first of these 
shows a valve on which there is no organized clot, but close 
examination reveals a thin deposit covering the entire surface 
with more clot at the point where the strut touchs-the centre 
of the occluder, and the third photograph shows a gross clot 
covering the entire surface. 
With milk it was found that, even where there is no overall 
clot deposition, it is still possible to find deposit forming 
discretely at a favoured site, and an example of this found 
in vivo is shown in the fourth photograph. 
4.8.3 Conclusions 
The apparent sequence of clot deposition found on heart valves 
with milk seems to be in accord with the sequence of deposition 
found with the Stagnation Point Flow Experiment. Furthermore, 
it is probable that the sequence of deposition is very 
similar to that found in the clinical situation. 
It must be noted that these proposed sequences of deposition 
on heart valves are based on results obtained in vivo at the 
end of experiments and each photograph belongs to a different 
trial. However since it is unlikely that large scale clot 
appears on the valves spontaneously, there must be a sequence 
of deposition, and the proposed sequence which is, supported 
by the photographs is the most probable. "''Y 
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Fig 125. Bjork-Shiley 




Fig 126. Bjork-Shiley Aortic Fig 127. Bjork-Shiley Aortic 
Downstream 40°C. 2L/min milk Downstream 40°C. 3L/min milk 
Fig 124. Bjork-Shiley Aortic 
Upstream 40°C. 2L/min milk 





Fig 129. Edinburgh Aortic Upstream 





Fig 131. Edinburgh Aortic 
Downstream 38°C. 3L/min m 
1 <<; ! L'8. Ediinburgh Aortic Upstream 
38 °C. 2L/min milk 
'J. Edinburgh dortig -131. 
Downstream 38cC. 2L/min milk ilk 
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Fig 133. Starr-Edwards Aor-tic 
Upstream 380 C. 3L/min milk 







Fig 134. Starr-Edwards Aortic 
Upstream 400 C. 2L/min milk 
Fig 135. Starr-Edwards Aortic 
Upstream 38 °C. 3L/min 
Fig 132. Starr-Edwards Aortic 
Upstream 400 C. 2L/min milk 
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The effect of altering the flowrate from 2 litres/min to 
3 litres/min on the amount of clot deposition is not very 
great. In general more clot is deposited at the lower flow 
rate, but it could be that this is due to the longer run times 
associated with the lower flow rate. 
Gross clotting, such that the valve function is prevented, 
only occurred in these tests at the lower flow rate (Figs 
136 - 138). 
0 }400-- 
ýý... ý 
Fig 136. Bjork-Shiley Aortic Fig 137. Flat Disc Mitral 
Downstream 400C. 2L/min milk Downstream 430 C. 0.6% CaCl 2 
and rennet. 1.7L/min milk. 
Pulse 50 
- 4 
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Fig 138. Starr-Edward Aortic Downstream. Conditions as 137. 
This suggests that low flow on a valve is potentially very 
dangerous. The flow velocity through the valve, and hence 
the shear stress, can become very low if a large valve is used 
in a damaged heart, and a trade off between the pressure drop, 
which is related to the 4th power of the diameter of the valve, 
and the enhanced possibility of valve failure through massive 
clot deposition is required. 
The flow rates used in all the experiments described are lower 
than that found physiologically, which is 70m1 stroke x 70 
pulse rate 5 litres/min, but it appears that this may not be 
critical. However, it must be borne in mind that the flow rates 
are low, and the maximum possible flow rates should be used in 
the tests. This is limited to 3 litres/min in the case of the 
apparatus used for these experiments. 
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Fig 141. bjork-Shiley Mitral 
Downstream. Same run as (139) 
Aa 
Fig 140. Bjork-Shiley Aortic 






Fig 142. Bjork-Shiley Aortic 
Downstream. Same run as (139) 
Fig 139. Bjork-Shiley Mitral 
Upstream 400 C. 3L/min milk 
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Fig 143. Edinburgh Mitral 
Upstream 400 C. 3L/min milk 
Fig 144. Edinburgh Aortic 










i i; ° 14E>. Starr-Edwards Aortic 
Upstream 400C. 2L/min milk 
'-N 
q9 
Fig 145. Starr-Edwards Mitral 
Upstream 400 C. 2L/min milk 
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Discussion 
The rennet, CaC12 and milk are not mixed together until they 
enter the perspex chambers of the artificial heart, just 
upstream of the mitral valve, at which time the clotting 
reaction is-initiated. It takes 10 - 15 seconds for the bulk 
of the milk to reach the aortic valve so that bulk coagulation 
which takes 30 - 40 seconds at the temperature used is then 
more imminent. There is also a considerable residence time 
distribution and in some regions of the chambers where the 
fluid is relatively stagnant coagulation occurs on the walls. 
This clot appears to remain attached and does not interfere 
with the clotting on the valves. 
A much smaller flow disturbance is therefore needed to cause 
clotting on the aortic valve than the mitral valve in the 
artificial heart used here, and the amount of clot found on 
Fig 147. Starr-Edwards Mitral Fig 148. Starr-Edwards Aortic 
Downstream. Same run as (145) Downstream. Same run as (146) 
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the aortic valve is greater than that associated with the 
mitral site. This is illustrated by the photographs of 
the Bjork-Shiley and the Edinburgh valves. The two 
photographs of each are taken of valves used in the same run, 
one in the mitral position and the other in the aortic 
position, and it can be seen that in each case there is more 
clot on the aortic valve than the mitral. Thus, the aortic 
position is a more severe test of the valves' clotting 
propensity in these experiments than the mitral position. 
In the case of the Starr-Edwards valve the importance of 
position is not quite so clear, and although the results 
shown are obtained from consecutive runs the conditions 
pertaining were identical. The quantity of deposit appears 
similar in both cases, but the nature of the deposit appears 
very different; the deposit on the mitral valve appears very 
much more grainy than that on the aortic valve. On closer 
examination, it can be seen that where clotting does occur on 
valves in the mitral position this granular appearance is 




Fig 157. Edinburgh Mitral Duwnstream 
40°C. 3L/min milk 
Fig 158. Flat Disc Mitral Downstream 
40 °C. 2L/min milk 
* 
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The explanation for this diversity, in the nature of the deposit 
is probably that despite the precautions taken to exclude air 
from the system it is still present, albeit in small volumes, 
in the mitral chamber and this air becomes involved in the 
deposition. Air is known to promote embolus formation in 
vivo (61,210,60,211,212,213) and, as previously discussed 
transient negative pressures have been observed during the 
valve cycle (52). It may be that the presence of air 
dissociated from the blood by this negative pressure leads 
to enhanced clotting and yields a clot of more granular nature 
than usual. There is, however, ", no direct evidence for this. 
Conclusions 
The position of the valve in the artificial heart used is a 
very important factor in determining the quantity of 
deposited clot. It does not appear to affect the position 
of the clots, but can affect the appearance of the deposit 
due to the presence of air in the mitral chamber. 




Fig 151. Bjork-Shiley Aortic 
Upstream 400 C. 3L/min milk 
i-ig 149. Flat Disc P^, itral Fig 150. Flat Disc Mitral 
Downstream 43 °C. 2L/min milk Downstream 36°C. 2L/mir, milk 
Fig 152. Bjork-Shiley Aortic 
Upstream 370 C. 3L/min milk 
- 133 - 
Discussion 
Temperature was shown to affect the clotting time of milk 
in Chapter 3. The above photographs (Figs 149,150) show the 
effect of a 7°C difference in temperature, despite the 
greater concentration of rennet and calcium chloride at the 
lower temperature case which would be expected to give 
greater clotting., The effect of a1- 2°C change in 
temperature is sometimes marked (Figs 151,152) and the results 
suggest that the temperature needs to be controlled + 0.5°C. 
The effect of changing. rennet and calcium chloride concentrations 
was found to be of less significance within fairly wide limits 
e. g. ' 0.8 - 1.2%. This was intentional and the concentrations 
were chosen to achieve this. A 2% concentration of rennet and 
calcium chloride would have given even greater stability, but' ' 
due to the expense of these two chemicals this was not 
convenient. 
3 
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4.9.4 The Effect of the Valve Materials and Surface 
Fig 153. Delrin Flat Disc Mitral 
Downstream 40°C. 2L/min milk 
1% rennet and CaC12 
Fig 154. Carbon Flat Disc Mitral 
Downstream 38°C. 2L/min milk 
1% rennet and CaC12. NB Run 
stopped as flow reduced due to 
Aortic Valve clotting. 
Discussion 
The effect of the materials of which a valve is made and the 
cleanliness of the valve must be of paramount importance. If 
a valve has been cleaned in an enzyme detergent prior to a 
run and has not been sufficiently rinsed afterwards, clot 
deposition will be inhibited and if the valve has not been 
properly cleaned clot deposition will be promoted. The 
photographs show the difference in clot deposition when two 
valves of similar design are used under similar conditions 
but whose material of construction is different, one being 
made of carbon and the other delrin. In the case of the carbon 
valve there is a clot adherent to the ring but very little 
clot attached to the occluder, whereas in the case of the 
delrin valve there is clot over the entire surface of the 
occluder. 
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This disparity between the performance of different 
materials makes it very difficult to compare valves of 
different designs, as has previously been mentioned. One 
solution to this problem would be to find a substance which 
could be used to coat all the valves used thereby removing 
surface effects. Albumen was tried, but some surfaces 
adsorb it better than others, so no advantage was gained. 
The importance of the surface poses another problem. If the 
analogue method is to be used for testing prototypes, it is, 
vital that these prototypes should be polished and prepared 
uniformly before testing. The problem of surface has 
affected the results of the clotting trials on the Edinburgh 
valve, and an even covering is found over the entire surface 
in nearly all cases. This might not occur if carbon valves 
were available, as can be seen from the flat disc results 
above. 
The surface properties are also important in the clinical 
situation or indeed in animal trials (48,214,215,44,216, 
45,46,12,41,134,217,48,133,49,50) so this 
disadvantage is not peculiar to the use of milk. 
It would be very useful if work could be done comparing the 
effect of various materials and surfaces on blood and milk 
depositions to see if there is any relationship between them. 




The notion that it might be possible to use the 
deposition of milk curds as an analogue for the 
deposition of blood seems at first glance somewhat far 
fetched. The deposition of solid constitutents from 
blood is extremely complex and as yet not fully 
understood. Milk is apparently a much simpler fluid, 
being a suspension of micells and fat globules which have 
little in common with the platelets, erythrocytes and 
leucocytes present in blood. The role of the coagulation 
of the two fluids is also very different; the clotting of 
blood occurs to heal wounds of the carrier animals, 
whereas the physiological purpose for the clotting of 
milk which occurs in the stomach of infant mammals, appears 
to be to educate the stomach for solid food. Another 
fundamental difference between the two is that all the 
chemical species required to initiate clotting in blood 
are present in the blood, whereas milk requires the 
addition of a coagulating agent, ' rennin, to initiate the 
clotting reaction. 
However, there are also reasons for expecting the two 
fluids to behave in a similar'fashion in respect of their 
essential clotting and deposition properties. Milk is 
largely dreived from food products in the-blood by the 
action of a mammary gland, and all the ingredients of 
milk must have originated in the blood. Fibrinogen and 
k-casein, the 
main 
proteins involved in blood and milk 




Both coagulation reactions involve the proteolytic splitting 
of a protein by the action of an enzyme and, furthermore, 
the kinetics of the two reactions appear to be the same 
(113). Both fluids are a suspension of particles in a 
serum, the fat globules apparently behaving in a manner 
analogous to the behaviour of the platelets in blood 
which are known to be of great importance during the 
inception of thrombosis (10,39,125,138,218,136, -219, 
24,220,221,222,15,16). 
5.2 Stagnation Point Flow Experiment 
The results of the work done using milk in the 
stagnation point flow chambers to compare the 
microscopic deposition of rennetized milk on a glass 
slide with that found by Petschek et al, using canine 
blood (11,12,33) support the hypothesis that there is 
a parallelism between milk and blood. The appearance 
of the deposits and the sequence of deposition appear 
to be very similar. 
The stagnation point flow experiment is-. very difficult to 
perform using milk, as the flow rates, are very.. low. If 
a milk flow-, of 2-4ml/min-is_used the flows, of rennet 
essence and calcium chloride solution will be, only 
. 05m1/min and obtaining good mixing at, these flow rates 
is very difficult. This experiment is of ; limited. value 
and I would not recommend its further use. 
_. _µ. 
5.3 Net Experiment 
Hladovec's net experiment,. (140),, on. the, other hand, proved 
to be very useful and-simple. The pressure variation curve 
upstream of, the filter mesh, was found to be the same for 
ä 
ý' 
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both milk and blood, and clot was found to form downstream 
of the mesh when rennetized milk was circulated, as had 
been found with blood. Although the time lapse before the 
pressure began to rise was not affected by the material 
or size of the mesh, the size of the clot adhering to the 
mesh after the run depended on the material used, which 
one would expect from the work on the adhesion of 
coagulating casein to various surfaces done by Berridge 
(79). The net experiment was also used for obtaining the 
relationships between clotting time and temperature, rennet 
concentration and calcium chloride concentration to 
ascertain the optimum conditions for use in a large scale 
heart valve testing apparatus., 
5.4 The Testing of Heart Valves 
The results of the full scale testing of the analogy 
between milk and blood deposition were as good as the 
results of the stagnation flow experiment and the net 
experiment had suggested they would be. The patterns 
of deposition on the various types of valve tried 
corresponded very closely to the deposits found on heart 
valves used in vivo with the exception of the Starr-Edwards 
valve struts. Very little clot is found in the clinical 
situation, whereas in the test rig extensive clots were 
found. This is apparently due to the inadequacy of the 
heart model to mimic the natural heart. The model heart 
is constructed in rigid Perspex. and. does not, therefore, 
collapse during systole like. the natural heart. The forming 
clot is not, 
_therefore,, 
dislodged in; the experimental set 
up where it probably is in vivo. 
This is probably desirable, for if the clot is forming and 
then being dislodged, the thromboemboli thus created can be 
very dangerous, and it is important to know if. this is 
i 
Z71 
happening. By allowing the formed clot to remain 
adhering to the struts it can be seen immediately that 
they are a site for thrombus initiation and propogation, - 
which is very useful knowledge for a designer of a 
heart valve. 
The sequence of deposition onto the valve was found to be 
the same as that found with the stagnation flow chamber 
and the net experiment, and the conditions prevailing were 
found to affect the deposition. Perhaps the most 
important observation is the effect of the material of 
construction of a valve on the amount of deposit 
adhering to it. This makes comparison between valves 
of different design and made of different materials very 
difficult. If a designer wishes to test the effect of a 
different design he must ensure that not only are the 
materials of different designs the same, but also the 
preparation of the surface, such as polishing and cleaning, 
is the same in all cases. 
It must be stressed that bulk coagulation of the milk used 
for testing heart valves does not occur until it leaves the 
chambers and reaches the drain. Thus any clot forming on 
a valve is not due to bulk coagulation of the milk at that 
point, but is related to come local fluid mechanical 
disturbance; be it a region of stasis, impinging flow 
leading to stagnation or high mass transfer. The presence 
of a high level of shear stress, as for instance might be 
found on the ball of the Starr-Edwards valve, causes that 
surface to remain clear from clot. Further evidence that 
the phenomenon of deposition observed is not merely that 
the bulk milk has become destabilized and will deposit 
anywhere is the importance of the materials of the surfaces. 
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Certain parts of the chambers where the flow was 
particularly slow or areas of stasis occurred favoured 
clot deposition and large clots formed in these areas. 
These deposits did not dislodge during the runs so no action 
was deemed necessary to prevent them, however, they did 
prolonge the cleaning time needed between runs. The 
finding of deposits on the chambers illustrates the 
potential of the analogue technique for testing other 







CONCLUSIONS AND RECOMMENDATIONS FOR FURTHER WORK 
6.1 Conclusions 
On the basis of the preliminary investigative work 
described here, rennetized milk can be used as an 
analogue fluid for testing the thrombogenicity of 
articifical implant devices. It must be borne in mind 
that the test cannot yield information on the effects a 
device might have on the blood chemistry, nor on the 
effects of a modification of the surface chemistry on the 
thrombogenicity. However, in circumstances where the 
clotting mechanism may be activated, which pertains to most 
cases of artificial device implantation, and where the 
deposition is flow related, the use of rennetized milk 
as an analogue of blood can yield rapid, cheap, 
reproducible results which do not necessitate the use 
of a surgical team. 
Furthermore, the following conclusions have also, been 
reached: - 
1) In the design of artificial heart valves it, is 
important that parts which intrude into the 
heart should be avoided, because, as-the heart 
contracts any small clots forming on the 
impediment will be dislodged leading to 
thromboembolism. 
2) The sequences of the deposition of rennetized 
milk and blood appear to be be similar and the fat 
globules in milk appear to mimic the behaviour of 
the platelets in blood. 
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3) The material of construction of a valve is 
important in determining the extent of the 
deposition onto it with milk as well as blood. 
4) A minimum concentration of 1% rennet essence and 
1% saturated calcium chloride and a temperature in 
the region of 40°C were found to yield satisfactory 
results. 
5) The deposition phenomena observed are not due to the 
bulk coagulation of the milk but are related to 
local fluid mechanical disturbances, which would 
also give rise to similar deposition phenomena 
with blood. 
6.2 Recommendations for Further Work 
The present control system of the valve tester should be 
improved. The temperature needs to be controlled to 
+ 0.5°C which cannot easily be managed with the present 
feed-back system controlling only one element in the hot 
water tank. A feed-forward computer controlled or a more 
sophisticated feed-back system would be desirable. The 
rennet and calcium chloride addition has been improved 
by the use of a metering pump with a plastic pump head. 
A method for negating the influence of materials used needs 
to be found, which might involve coating the device under 
tests with a substance of uniform chemical properties. 
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